Page 11234..1020..»

Archive for the ‘Life Extension’ Category

H Lundbeck A/S : Lundbeck receives exclusive rights to APB-A1, an innovative phase I-ready bio-therapeutic for the treatment of neuroimmune diseases…

H. Lundbeck A/S (Lundbeck) announced that it has entered into a definitive agreement with AprilBio Co., Ltd. (AprilBio), a biopharmaceutical company based in South Korea dedicated to developing specialized biologics and antibody drugs.

Under the agreement between the two companies, Lundbeck receives exclusive, worldwide rights to research, develop and commercialize APB-A1, a novel and well-differentiatedanti-CD40 ligand (CD40L) antibody-like drug candidate,readyfor phase I testing around the beginning of 2022. This novel drug candidate offers significant potential across a wide array of neuroimmune diseases.

Dr. Johan Luthman, EVP and Head of Research & Development in Lundbeck, said:

"I am excited to announce this partnership with AprilBio around their interesting novel anti-CD40L antibody-like molecule that accelerates our R&D strategy within neuroimmunology, one of our four strategic biological focus areas. Based on promising preclinical data, this project has the potential to offer new, potent and differentiated therapies for several different types of neuroimmune diseases".

The agreement enables Lundbeck to initiate clinical activities targeting the neuroimmune system. The concept is built on a biology that has proven its ability to therapeutically target diseases of the central nervous system. APB-A1 will accelerate internal experience and expertise that in turn will enable building a broader pipeline for Lundbeck in this area.

"We are also glad to join hands with Lundbeck, which leads the global brain disease treatment industry," AprilBio CEO Dr. Sang-hoon Cha said in a statement. "We expect that possibilities to successfully develop a new drug for treating multiple neuroimmune diseases will increase through this partnership."

Under the terms of the license agreement, Lundbeck will make a one-time payment to AprilBio of USD 16 million in cash. In addition, Lundbeck will pay AprilBio success-based development, regulatory, and sales milestone payments of up to USD 432 million related to APB-A1. Lundbeck will also pay AprilBio tiered royalty payments with the highest tier reaching low double-digit percentage of net sales. Lundbeck will be responsible for all future development activities and expenses related to the project.

About APB-A1APB-A1 is a neutralizing anti-CD40L antibody-like drug candidate with an innovative molecular design blocking the essential CD40L/CD40 co-stimulatory interaction. The activation of the CD40L/CD40 signaling cascade is essential for the initiation of cellular and humoral immune responses. It is an established and clinically validated immune pathway through its ability to trigger activation, differentiation and proliferation of B-cells, T-cells, and several other immunes cells (such as monocytes, macrophages, dendritic cells, natural killer cells) to mediate immune responses. Modulating the CD40L/CD40 interaction therefore holds great promise for treatment of a wide range of autoimmune related CNS disorders and neurological diseases.

APB-A1 is a human, high affinity, anti-CD40L antibody-like fusion protein that is designed to inhibit the CD40L/CD40 pathway through neutralization of CD40L presented on activated T-cells, and consequently significantly attenuating the initiated immune response. In preclinical studies, APB-A1 has demonstrated engagement with CD40L leading to decreased antibody response and circulating inflammatory markers. One of the differentiating aspects of the APB-A1 design is its ability to utilize human serum albumin for half-life extension translating into superior clinical features.

About AprilBioAprilBio Co., Ltd. is a biopharmaceutical company in South Korea founded in 2013. The company is specialized in development of specialized biologics and antibody drugs. The company's platform technologies include a human phage-display Ab library and Anti-Serum Albumin Fab-Associated (SAFA) technology (versatile building block for half-life extension and generation of novel biological therapeutics). AprilBio is focused on rare diseases, oncology, autoimmune and inflammatory diseases.

Contacts

About H. Lundbeck A/SH. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

Too many people worldwide live with brain diseases - complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Every day, we strive for improved treatment and a better life for people living with brain disease.

We have approximately 5,600 employees in more than 50 countries, and our products are available in more than 100 countries. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options. We have research facilitiesin Denmark and the United States, and our production facilities are located in Denmark, France, and Italy. Lundbeck generated revenue of DKK 17.7 billion in 2020(EUR 2.4billion; USD 2.7billion).

For additional information, we encourage you to visit our corporatesitewww.lundbeck.comand connect with us on Instagram (h_lundbeck), Twitter at@Lundbeckand viaLinkedIn.

H. Lundbeck A/S

Ottiliavej 9, 2500 Valby, Denmark

+45 3630 1311

info@lundbeck.com

https://news.cision.com/h--lundbeck-a-s/r/lundbeck-receives-exclusive-rights-to-apb-a1--an-innovative-phase-i-ready-bio-therapeutic-for-the-tr,c3432091

https://mb.cision.com/Main/18215/3432091/1480764.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

Continued here:
H Lundbeck A/S : Lundbeck receives exclusive rights to APB-A1, an innovative phase I-ready bio-therapeutic for the treatment of neuroimmune diseases...

Who wants to live forever? Big Tech and the quest for eternal youth – New Statesman

The summer before she started her neuroscience degree at the University of Texas, Celine Halioua interned at a clinic in Germany, working with patients who had age-related brain cancer. She formed a bond with one of them. He had a large, bushy moustache and a permanent smile the picture of a kind father, she told me. My German was not great, and neither was his English, but what struck me was his kindness despite the fact he was there to discuss his terminal diagnosis.

Halioua was shadowing a doctor, and found it hard to grasp that nothing could be done for this patient. I always thought that doctors were magical that if you put the effort in, youd be able to fix it. The realisation that you cant made me feel that we dont have free will.

She resolved to find that fix: not a cure for cancer, but an end to ageing itself. Now, at only 26, Halioua is a leading light in the relatively new field of anti-ageing biotech. Im confident well have an ageing drug by the time its relevant for me, she told me. She estimated that time as within a decade, and aims to dominate the market before then. Transparently, my goal is to build the ageing pharma company there will be many. The ageing field will one day be larger than the cancer field. Halioua described ageing as deviation from optimal biological function. Optimal is subjective, of course: Olympic gymnasts peak at a much younger age than Olympic sprinters. Old is easier to define: Halioua described it as when the physical body gets in the way of the thing that you want to do.

Haliouas speech was so rapid that the internet connection from her office in San Francisco could barely keep up. She looked every inch the digital nomad in her black T-shirt and AirPods: part biogerontologist, part CEO, part Gen Z-er. Haliouas mother is Moroccan and her father German; she was born in Texas but studied in Sweden, Germany and the UK, and dropped out of her PhD at Oxford University and began to work for the venture capitalist Laura Deming, now 27, at the California-based Longevity Fund, a firm that invests in anti-ageing businesses. Halioua launched her own start-up in 2020.

The quest for eternal youth may not be new, but it is now bankrolled by some of the wealthiest individuals and corporations on Earth. PayPal co-founder Peter Thiel and Oracles Larry Ellison are among the many billionaires who are investing. Google founders Sergey Brin and Larry Page helped launch Calico, a Google subsidiary focused on combating ageing, in 2013. Amazon founder Jeff Bezos is in the game: not long after touching down from his maiden space flight in July, he was reported to have invested an undisclosed sum in Russian billionaire Yuri Milners Altos Labs, which will have a research base in Cambridge, UK (most anti-ageing start-ups are in the US). It is estimated that the industry will be worth $610bn by 2025.

[See also: The internet was built for connection how did it go so wrong?]

The field shouldnt be confused with the kooky subculture of life extensionism, whereby the determined and ascetic experiment with severe calorie restriction, intensely calibrated exercise and cocktails of daily supplements in a bid to extend a life that is arguably not worth living. Instead, anti- ageing science works at the level of gene therapy, cell hacking and reconstituting human blood; the medical treatments at its heart are based on bleeding edge science and aimed at the mass market. Some focus on biological reprogramming: adding proteins known as Yamanaka factors to cells, causing them to revert to a previous state. Others look at genomic instability or the way DNA damage that accumulates over time might be repaired.

The entrepreneurs in this fledgling field are determined that the end of ageing will come via therapies approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The elixir of youth wont be a single drug, but a regimen of treatments that knock out different hallmarks of ageing and allow us to get older without losing our bodies and minds. We will still die: there will be accidents as well as diseases unrelated to age (children still get fatal cancers, after all). But death will become increasingly remote, and no longer preceded by years of inevitable decline.

Its advocates argue that, once ageing is cured, the financial, medical, societal and emotional burden of taking care of the elderly will disappear. But have these entrepreneurs thought about what a post-ageing world would look like? And if they have, would anyone want to live there?

As it stands, a drug will only get regulatory approval if it is marketed as a treatment for age-related diseases such as arthritis, cataracts and macular degeneration, diabetes, certain cancers, dementia and Parkinsons rather than ageing in its own right. This, then, is where the science is focused. The thinking is that, if the ageing processes that underlie those diseases are treated, other rejuvenation benefits can be smuggled in.

Based in San Francisco, Unity Biotechnology is developing a class of anti-ageing drugs called senolytics. These work by eradicating senescent cells those that have stopped dividing and then gather in the body, spewing out factors that harm the surrounding tissue. Its a completely new way both of thinking about a disease and targeting it, Anrivan Ghosh, Unitys CEO, told me. Senolytics reprogramme the tissue. They raise the possibility that I can restore a previous state that a tissue or a body was in. It was first thing in the morning for Ghosh (we were speaking over Zoom), but he was fizzing with enthusiasm. He is 57 but looks younger, with a neat goatee and hair that is only flecked with grey.

Senolytic drugs are designed to be taken prophylactically, during what Ghosh refers to as a window of time when senescent cells are known to accumulate (this varies in different parts of the body). He was keento tell me about Unitys ongoing clinical trial in people with age-related eye disease the first evidence of a senolytic treatment working, he said. Twelve patients with severe vision loss due to macular degeneration or diabetic macular oedema (two of the major causes of age-related blindness) had been put on a course of Unitys lead senolytic. One of the patients could not see any letters on an eye chart, even with her glasses on, from four metres away. Everything she once needed help with, she can now do independently. The majority of those patients showed an improvement.

I would have been happy if they just maintained their vision, Ghosh said. It raises the possibility that you may somehow be able to reverse trajectory and restore a better state. Thats another level.

[See also: The fidget business]

Unity was an early success story, with Peter Thiel and Jeff Bezos signing up as seed investors. People like Thiel and Bezos arent interested in financing the kind of incremental gains a next-generation medicine might offer, Ghosh told me. They are drawn to the idea of being able to do something that changes the way we think about disease, that changes the way we live. Over time, Unitys funding has come increasingly from bigger, more mainstream investors.

Promising paradigm change can be a risky business. Unity was valued at $700m at its initial public offering in May 2018, but shares fell by more than 60 per cent in August 2020 after its flagship product, a senolytic treatment for osteoarthritis of the knee that had worked on mice, was shown to have no greater effect than a placebo in human trials. It tells you something about the translational gap in that case sometimes the animal studies do not replicate in the human case, Ghosh said. There will be many bumps before we have success.

Up to 30 biotech companies around the world are developing senolytic drugs. British biogerontologist and computational biologist Andrew Steele, who wrote his book Ageless: The New Science of Getting Older Without Getting Old (2020) while studying nematode worms at the Francis Crick Institute in London, told me he thought we were two or three years away from having the first senolytics in the clinic for specific conditions. It could be within a decade that were using these things preventatively. Like most other advocates, Steele was ambitious about the timeframe, given the relatively small number of human trials.

Ageing isnt officially defined as a disease, which is a problem for the biotech companies, Steele explained. Its currently very difficult to get a drug approved because it isnt an indication in the pharmaceutical industry. That means theres no way to say, Ive reversed or slowed someones ageing. But he remained optimistic. Were in a position, unique in human and scientific history, where weve finally got a handle on the processes. Unless youre very old or very, very unwell, theres going to be an anti-ageing drug in time for you.

For Steele, who is 36, this cant come soon enough. We have been completely ignoring the single largest cause of death, human disease and suffering, he told me. I dont think barbaric is too strong a word. Being old steals your independence: its what puts you at risk of all kinds of things not just the internal stuff like cancer and heart disease, but external threats like falls, infectious disease.

Steele told me about some 24-month-old mice (around 70 in human years) he had observed in a lab while researching his book. After a dose of senolytics, the mice thrived. They get less cancer, fewer cataracts, fewer heart problems, they are fitter and less frail, he said. Theyre cognitively younger as well. And they have better fur, thicker, plumper skin, less grey hair they just look fantastic.

Celine Halioua doesnt have to worry about the translational gap between mice and humans. She left the world of longevity venture capital in 2019 to become founder and CEO of Loyal, a biotech start-up dedicated to extending dog lifespan. It aims not simply to stretch the length of time a dog can live anything from an extra six months to three years, depending on the breed but to ensure that those months and years are healthy. (Halioua herself is a devoted dog owner, and lists her husky, Wolfie, as the companys chief evangelist on the Loyal website.) But dogs are just the beginning. Were planning to take what we learn in dogs to help pet parents and non-pet parents live longer, too, she told me.

Dogs develop the same age-related diseases as we do, Halioua explained, at approximately the same point in their life-span (the exception being heart disease, because they dont eat a lot of McDonalds or whatever). Their fur loses pigment and goes grey, just like their owners hair. They share an environment with us, and environmental factors are huge in ageing. Its also possible to see whether an intervention is working much sooner in dogs than in humans: You can do a preventative measure when theyre two or three, and youll know by six or seven, probably sooner, whether the intervention did or did not do the thing. Dogs will make the pathway to regulatory approval smoother, Halioua believes. If something can work in a complex species like a dog, that isnt super-inbred like a mouse, its a more robust justification to pursue that in people.

Significantly, dogs have devoted owners who are prepared to pay over the odds though Halioua said she was determined not to exploit that devotion. It is important to me to price our products so that they are accessible for the majority of dog owners. The final cost will depend on the materials but, order of magnitude tens, not hundreds, of dollars a month.

The first of two Loyal drugs in development targets cellular mechanism and glucose metabolism in large- and giant-breed dogs. Due to a quirk of animal husbandry, the larger the dog, the shorter its lifespan. A Great Dane might live seven to nine years on average, while a Chihuahua might live 16 to 18. Thats weird. You normally dont see a times-two differential in lifespan within the same species you dont see it in people of varying heights. This, Halioua explained, was due to an antagonistic pleiotropic effect: the thing that caused the dog to grow big quickly has a negative impact on lifespan.

The second drug targets metabolic fitness in dogs of any breed and size, in order to replicate the same effect on lifespan that calorie restriction does in mice. This will be better for late-in-life intervention. Of course, prevention is optimal, but there are people who already have grey-faced dogs and we wanted to have something for them. Trials are due to begin next year.

Other anti-ageing therapies have emerged from more gruesome animal experimentation. The biotech company Elevian, founded in Silicon Valley but now based in Boston, began 15 years ago after Harvard professor of regenerative biology Amy Wagers stitched live mice together, fusing the circulatory systems of old and young specimens, in a process called parabiosis. The mice lived fused together for four weeks before their organs were removed and studied. Elevians CEO and co-founder, Mark Allen, described an experiment that sounded like Frankenstein and Dracula combined: The old mice exposed to young blood grow biologically younger by many different measures, and the young mice exposed to old blood grow older.

[See also: The spirit of the age: Why the tech billionaires want to leave humanity behind]

A 51-year old medical doctor turned tech entrepreneur, Allen told me he had read about Wagers work and thought it might be turned into a therapy. But its not an easy thing to translate. In the parabiosis model, the old animals are getting a continuous transfusion of young blood, 24/7, for four weeks. You cant really have a blood boy tied to you, he said, with a dark grin.

The Harvard team identified the recombinant protein GDF11, the critical factor circulating in blood that appears to be behind the rejuvenating effect. Just injecting GDF11 once daily was able to reproduce many of the different effects, Allen said. I fell in love with this work because of the breadth of effect. He reeled off a list of diseases that GDF11 might combat: emphysema, cardiovascular disease, fatty liver disease and potentially some cancers.

Still, Elevian had to choose one specific indication they could tell regulators they were targeting, and decided its best bet was stroke: the worst possible disease that we could treat for the shortest possible duration, and see clinically meaningful effects, Allen said. Stroke is the second biggest cause of death worldwide and a leading cause of long-term disability; the few treatments that currently exist need to be given within a few hours after a stroke if they are to be effective.

Allen said animal trials were looking positive. When we give GDF11 after a stroke, it significantly improves sensory motor function recovery. And we can give it late we can start it 24 hours or later when no other treatments exist. Our primary focus today is taking it into clinical trials. For Allen, this would be the start of something more ground-breaking. Part of the game is getting it to market as soon as possible and then beginning to expand its indication.

The entrepreneurs I speak to might be taking different paths to eternal youth, but they agree on one thing: ultimately, ageing will be cured. None wants to hazard a guess at how long people will live there may be some yet unknown physical side effect that we discover in our 200s but they believe the only obstacle to an infinite human lifespan is our inability to imagine what that might look like. This means that the potential negative effects can only be raised delicately. The ageing process causes two thirds of death globally, Steele reminded me. Any objection you want to come up with to say we shouldnt do something about it has to be larger than that.

But Paul Root Wolpe, 64, director of the centre for ethics at Emory University in Georgia in the USA (and a former senior bioethicist at Nasa), told me that a world without ageing would be an economic disaster. The argument some advocates make for its enormous social benefits is a misdirection, he said. I find their arguments extremely naive, sociologically unsupportable, and most importantly, deeply narcissistic. Ive never heard a single plausible argument of how radical life extension would benefit society only an egocentric desire not to die. The truth is, they want to stop ageing. They want to live healthily to 150.

In Wolpes view, anti-ageing scientists and entrepreneurs minimise or ignore the profound implications of significantly increasing the human lifespan. The International Monetary Fund has stated that an ageing population in Japan has led to a vanishing labour force, higher demands for social services, a shrinking tax pool, greater wealth disparities and thats just from living what is currently our lifespan. If we increase it, all of those things would increase exponentially.

But in the future envisaged by the biotech start-ups, we would work into our hundreds: an elderly population would still be a labour force. Wolpe had little patience for this idea. That is a profoundly elite perspective. Do you really think that the longshoreman, the hard labourer, the person who works as a clerk in a store, at the age of 65 is going to say, Great! I get to work for another 50 years! Its absurd. Polls show that large percentages of people hate their job. Elitists who work entirely with their brains are a small minority of the human population. They have a very blinkered point of view. It was no coincidence that Silicon Valleys tech billionaires were early investors, Wolpe said. This is one of the great scientific, intellectual areas to conquer. These people have already conquered the world in new ways. They are the first group to touch the lives of hundreds of millions, if not billions, of people. They have so much cash, and they dont know what to do with it.

The political ramifications of an indefinite lifespan are equally huge, Wolpe argued. The elderly vote at much higher rates than the young, and, in America at least, the highest echelons of power have become the preserve of the over-70s. Politically, young people will be squeezed, and the fresh ideas they bring to politics and innovation more generally will be suppressed.

Do you think that if the last generation or the generation before that lived to 100 or 150, there would be gay marriage, diversity inclusion movements, #MeToo? Wolpe said. The vast majority of the great innovations of the last 50 years were created by young people. A life well-lived hands its torch to the next generation. It doesnt try to override them for its own narcissistic needs.

Overpopulation and the climate crisis are other obvious counter-arguments. If death becomes rare, and humans remain at optimal health, how soon will the world run out of space and resources? Wont humans die from starvation and natural disasters instead?

[See also: Toxic relationships, burnout, productivity dysmorphia why do we medicalise societal problems?]

This is not a technology in isolation, Allen argued when I put this to him. Were figuring out how to have cleaner energy, how to have food that is healthier and less polluting, how to live more peacefully, how to travel into space. There is not a real estate problem here on Earth if we live better. Its an argument typical of Silicon Valley optimism: the solution is always more tech.

Im sanguine about overpopulation, Steele told me. If we had to work a little bit harder to solve things like climate change, resource use, land use and all those things that Im genuinely concerned about, Id happily do so if it meant suddenly no one was dying of cancer or Alzheimers.

Both Steele and Halioua dismissed the idea that indefinite fertility would lead to a population crisis, seeing it instead as an opportunity for a fairer world. Halioua pointed out that, if women want to have children, they are currently forced to make compromises at a critical time in their careers. Im going to be in my thirties soon, theoretically the ideal age to have kids, and Im not going to want kids at that age hopefully I will still be building Loyal. Thats a societal pressure that men dont have. [This] will free up 50 per cent of the population who inevitably have to take the hit.

Already, the wealthy live longer: men in the most deprived areas of England can expect to lead lives nearly a decade shorter than those in the wealthiest parts. Anti-ageing drugs will surely amplify these inequalities, when only the individuals and nations that can afford them can buy ever longer life-spans. Halioua said she had factored these concerns into her development plans: The ideal ageing drug is going to be like a statin, in terms of not being expensive. Steele added that this was a long game: expensive drugs have patents that expire after 20 years, after which generic drugs can be made at a fraction of the cost. Im not saying its right, but its normal for rich people in the West, and then everyone in the West, and then poorer countries to benefit from various kinds of medical intervention.

[See also: How life without germs has left us newly vulnerable]

I asked the anti-ageing entrepreneurs about Wolpes point that longer lives will increase intergenerational inequalities. In a future where people keep their minds and bodies, never losing their edge, how will the young ever compete in the workplace?

That kind of thinking assumes that if people were to live in good health for a very long period of time they would want to continue to do the same things, Ghosh said. I know I would not want to do drug discovery for the next 30 years. I have a bazillion other things Id like to do, and I would happily let other people take this role.

Halioua took the question personally. With Loyal, there are plenty of people who are double my age, in their 40s and 50s, completely cognisant, who have been working in ageing a long time, and didnt have the idea or desire to build this company, she said. Experienced people come with baggage and biases. Being naive has actually been one of my best traits, she said. In other words, the young will still wield their advantages.

Allen was the only anti-ageing advocate I spoke to who entertained any ethical discomfort. The biggest thing that concerns me is despots, dictators, he said. They die over time. With this, they might be able to live.

Even if we believe the claims these proponents of eternal youth make that the planet can cope, that societies will be no more unequal one problem remains: death. Its proximity directly affects our appetite for risk, making clinical trials into new vaccines possible, and encouraging billionaires to go into space. In a future where death occurs only as a result of rare disease, suicide or tragic accident, will we become paralysed by the fear of it?

For the first time, Halioua didnt have an answer. I dont know, she replied, after a long pause. I would argue that this is already a huge latent paralysis in the average human. Maybe it will get better. I dont see a world where we start becoming extra- terrified of car accidents, but maybe we will. Her face brightened: she had an idea. Maybe Tesla needs to get all their self-driving cars on the market and market it this way Number One Cause of Death Eliminated By Tesla! There it was again: the answer to a problem created by technology is more technology. The future looked bright once more and endless.

Jenny Kleeman is the author of Sex Robots and Vegan Meat: Adventures at the Frontier of Birth, Food, Sex and Death (Picador)

This article appears in the 13 Oct 2021 issue of the New Statesman, Perfect Storm

Read the original here:
Who wants to live forever? Big Tech and the quest for eternal youth - New Statesman

Tracerco secures subsea inspection for life extension project of over 18 risers in the Gulf of Mexico | Oil and Gas Technology – Oil & Gas…

Under the contract, Tracerco will deploy DiscoveryTM, a subsea computed tomography (CT) scanner designed for external scanning of pipelines and which operates along the same general principles as CT scanners used in hospitals.

As methods of oil and gas extraction have improved, many fields are still producing substantial quantities of oil and gas, and as such, operators are looking for methods to monitor and verify their risers condition to ensure ongoing integrity and extend their operational life. For life extension, regulators typically require a physical inspection to ensure the condition of the riser and CT, a technique which has an unparalleled ability to accurately and non-intrusively see through an item, can provide this information.

Technologies using CT such as DiscoveryTMprovide operators with valuable inspection data on the entire pipeline, spanning the range from product to coating and all areas in between. It is a non-intrusive external scanning technique and is easily capable of scanning through several inches of pipeline steel with no requirement to remove any protective coating, regardless of thickness and material.

Tracerco was the first company to develop a subsea CT system and still holds the fundamental patent for the concept of subsea CT scanning dating back to 2011, says Jim Bramlett, Commercial Manager North America for Tracerco, Over the years since, DiscoveryTMhas incorporated numerous additional patented innovations for optimizing the system.

DiscoveryTMwill be used to inspect the risers and determine whether they can be extended past their original design life by gathering real time data on a variety of integrity issues including pipeline corrosion, pitting and wall thinning. This will allow the operator to work with the local authorities to get their permit extended and potentially realise billions in continued revenues from the asset.

DiscoveryTMprovides the integrity insights to know the unknown enabling critical decisions regarding life extension to be made, continues Jim, and it does this while the risers are still in full operation. No need to interfere with production.

Link:
Tracerco secures subsea inspection for life extension project of over 18 risers in the Gulf of Mexico | Oil and Gas Technology - Oil & Gas...

County moved to annex 10 years ago | News | athensreview.com – Athens Daily Review

News last week that after 20 years of an overcrowded courthouse, Smith County is purchasing property to build a new one, is a reminder of the move Henderson County made a decade ago.

After searching for years for the ideal space to put the overflow of Henderson County offices, Commissioners Court arrived with a solution. In February 2010, the county reached an agreement with Prosperity to purchase the building, with ideas of using it for offices and document-storage space. The cost was about $2.7 million.

In September 2011, the County Judge, County Clerk, Tax Assessor/ Collector, and other departments that had been in the Courthouse for nearly a century, relocated across South Prairieville Street to the Courthouse Annex, a 33,500 square-foot building that once housed the Prosperity Bank.

Then in October, Commissioners Court voted to begin holding meetings in the annex, first in a room next to the county judges office, then later in the larger County Courtroom that is used today.

Before deciding on the annex, the county discussed possible use of other properties that were available around the city and even looked at a site on Loop 7 North.

The bank building became vacant when Prosperity exited the property at the end of April 2011. Then, County Judge Richard Sanders, the County Commissioners, the IT Department and the Maintenance Office went to work getting the spacious structure ready for the move.

With space open in the courthouse, the county began moving out of the decaying annex building on North Palestine Street that held the tax office and the Texas Agri-Life Extension Office.

Not only did the move save the county money compared to other options, it also kept the county government presence downtown. Since then, downtown Athens has become a more vibrant area, with new businesses and the Texan Theater to draw people to the Central Business District.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

View original post here:
County moved to annex 10 years ago | News | athensreview.com - Athens Daily Review

Evolution sells Mt Carlton – Creamer Media’s Mining Weekly

PERTH (miningweekly.com) Gold miner Evolution Mining has struck a A$90-million agreement with fellow listed Navarre Minerals to sell its Mt Carlton gold mine, in Queensland.

Mt Carlton was Evolutions first development project and has generated excellent returns for shareholders since it was commissioned in 2013. With the company focussed on delivery of growth projects at the cornerstone assets in the portfolio, we believe now is the time to hand Mt Carlton over to an emerging gold producer who can focus on extending the operations mine life, said Evolution executive chairperson Jake Klein.

Under the terms of the agreement, Evolution would be paid an initial A$40-million on the completion of the transaction, comprising a cash component and up to A$20.4-million worth of Navarre shares.

Up to A$25-million will be payable on cumulative gold production milestones from Crush Creek with A$5-million payable upon achievement of 50 000 oz, A$5-million payable upon achievement of 100 000 oz and A$15-million payable upon achievement of 175 000 oz, while up to A$25-million will be in the form of a 5% gold price linked royalty where the average spot gold price is greater than A$2 250/oz in a given quarter.

The royalty is payable on production from both Mt Carlton and Crush Creek from July 2023 for up to 15 years.

The exposure we have retained will enable Evolution shareholders to benefit from the future success of the operation. Evolution would like to thank our employees, contractors, suppliers, the traditional custodians of the land the Birriah People, and the local community for their contribution to Mt Carltons success. We are confident that Navarre will be a great partner for those stakeholders in the future, said Klein.

Navarre on Tuesday told shareholders that the transaction would instantly transform the company into a self-funded gold producer with premier exploration assets across Victoria and Queensland.

Mt Carlton is a proven, high-margin operation and an attractive vehicle for Navarre to transition from gold exploration company to producer particularly given the Mt Carlton operations successful history of production and its potential for significant mine life extension, said Navarre MD Ian Hollland.

Under the transaction, Navarre will inherit a well-established operation and a highly experienced site operating team and workforce which we are confident will fit in with Navarres own culture and focus on potential for further discovery and resource addition.

To fund the initial A$40-million up-front purchase price, Navarre will undertake a fully underwritten placement consisting of some 533-million shares, at a price of 7.5c each, to raise up to A$40-million.

Evolution has agreed to participate in the equity raise, with the companys shareholding in Navarre capped at 19.9%, with the final shareholding to be determined after the equity raise has been concluded.

Navarre on Tuesday said that the balance of the placement proceeds would go towards associated transaction costs and general corporate purposes.

The Mt Cartlon transaction is subject to a number of conditions, including Navarre acquiring shareholder approval to conduct the share placement, and to issue shares to Evolution.

The Mt Carlton operations comprise an openpit and underground mine, and a 950 000 t/y processing plant situated on a tenement package of approximately 815 km2.

Future mining operations at Mt Carlton will be supplemented by the nearby Crush Creek deposit, which hosts an initial high grade resource containing 126 000 oz goldat 3.5 g/t from only nine months of concentrated drilling. This asset was acquired by Evolution in late 2020.

In the 2021 financial year, the Mt Carlton operations produced 58 371 oz of gold at an all-in sustaining cost (AISC) of A$1 937/oz, including A$19.6-million of net mine cash flow in the fourth quarter alone. The operationis expected to produce between 45 000 oz and 50 000 oz of gold in the 2022 financial year at an AISC of A$1 650/oz to A$1 700/oz.

Evolution on Tuesday said that the sale of Mt Carlton lowers group AISC by A$40/oz to between A$1 180/oz and A$1 240/oz and reduces 2022 production to between 670 000 oz and 725 000 oz. Sustaining and major capital also reduce by between A$2-million and A$8-million and between A$10-million and A$15-million respectively.

Here is the original post:
Evolution sells Mt Carlton - Creamer Media's Mining Weekly

Adagio Therapeutics Announces New Data Highlighting the – GlobeNewswire

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study

Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300 mg Intramuscular Dose of ADG20 Given as a Single Intramuscular Injection in Ongoing Phase 2/3 Studies

Data to be Presented During IDWeek 2021 and 19th Annual Discovery on Target Conference

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new data from the companys COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular (IM) dose given as a single injection that is being evaluated in the companys ongoing global Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of Americas IDWeek 2021, being held from Sept. 29 Oct. 3, 2021. In addition, Adagios chief scientific officer, Laura Walker, Ph.D., will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimization of this differentiated antibody clinical candidate in an oral presentation at the 19th Annual Discovery on Target Conference on Sept. 30, 2021.

The continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 which was designed to be potent, broadly neutralizing and delivered as a single IM injection could have on people with or at risk of COVID-19, said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of COVID-19. We anticipate these data will support an Emergency Use Authorization (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.

Phase 1 Trial UpdateAdagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics (PK), immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo against SARS-CoV-2. Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection. In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. Importantly, ADG20 was well tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions reported through a minimum of three months follow-up across all cohorts. Participants will continue to be followed through 12 months to assess safety and tolerability, PK, immunogenicity and serum virus neutralizing activity.

Phase 1 Poster Information: (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

Dose Selection StrategyTo support dose selection for Adagios global Phase 2/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole-body physiologically-based pharmacokinetic (QSP/PBPK) model to better characterize the PK of extended half-life monoclonal antibodies in serum and key sites of viral replication in the respiratory tract. Adagios model adequately a priori predicted the observed ADG20 serum PK in non-human primates (NHPs) and humans. The model was further optimized based on data from Adagios Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE.

For the STAMP treatment trial, data compiled to date suggest that the 300 mg IM regimen has a projected ability to rapidly achieve and maintain target concentrations at key tissue sites of viral replication, including the ability to attain near complete (> 90%) and durable (> 28-day) SARS-CoV-2 receptor occupancy across a range of baseline viral loads. Further, for the EVADE prevention trial, data compiled to date suggest the 300 mg IM regimen has a projected ability to rapidly exceed target serum concentrations in the majority of simulated patients and to maintain potentially effective concentrations for up to 12 months.

Dose Selection Poster Information

The STAMP and EVADE clinical trials are currently ongoing and enrolling patients globally. For more information, please visit clincialtrials.gov.

About ADG20ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio TherapeuticsAdagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The companys portfolio of antibodies has been optimized using Adimabs industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagios portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch. For more information, please visit http://www.adagiotx.com.

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as anticipates, believes, expects, intends, projects, and future or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA application, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading Risk Factors in Adagios prospectus filed with theSecurities and Exchange Commission(SEC) on August 6, 2021and in Adagios future reports to be filed with theSEC, including Adagios Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:Media Contact:Dan Budwick, 1ABDan@1abmedia.com

Investor Contact:Monique Allaire, THRUST Strategic Communicationsmonique@thrustsc.com

See the original post:
Adagio Therapeutics Announces New Data Highlighting the - GlobeNewswire

Crypto leaders are obsessed with life extension. Here’s why Cointelegraph Magazine – Cointelegraph

Ethereum co-founder Vitalik Buterin is on a mission to make humans immortal. Buterin, 27, proposes the idea that aging is an engineering problem.

He is not alone in his combined interest in Bitcoin and biohacking. Famous biomedical aging researcher Aubrey de Grey, Xanadu architect and Agoric chief scientist Mark Miller, Bitcoin Cash billionaire Roger Ver and former chief technology officer of Coinbase and a16z general partner Balaji Srinivasan, are all fascinated by the pursuit of longevity.

De Grey recently helped advise a decentralized collective funding longevity research. He says:

I have been gratified since the beginning of blockchain to see the enormous fanbase that I and the longevity movement have in there.

Miller, alongside his engineering hall-of-fame accomplishments, is a senior research fellow at the Foresight Institute, a not-for-profit founded in 1986 with the aim of advancing technology for the long-term benefit of life.

Im very much involved in this new world of crypto commerce, often referred to as the blockchain sector, he says. Im very hopeful about that as creating an ecosystem in which secure software will dominate because insecure software results in massive losses quickly, with no recourse.

Srinivasans Twitter bio describes his vision as: Immutable money, infinite frontier, eternal life. #Bitcoin. Srinivasan states that the ultimate purpose of technology is to eliminate mortality and life extension is the most important thing we can invent.

Blockchain communities are clearly excited about longevity. But what does cryptocurrency have to do with life extension, and where might this future be headed?

It turns out that the link between crypto and cryogenics stretches back to core contributors, and the Cypherpunks mailing list and its links to transhumanist groups, including the first person to transact Bitcoin with Satoshi, Hal Finney.

Crypto philanthropists are donating significant wealth to this area, which is typically difficult to garner mainstream support for. They may be the only people on the planet optimistic enough to fund tech that currently only exists in sci-fi novels.

According to Buterin, longevity is a battle worth fighting for. Buterin donated $25 million in SHIB cryptocurrency tokens to the Future of Life Institute in June 2021 and has donated over $350,000 to the SENS Research Foundation to reimagine ageing.

He discussed the topic in recent podcast interviews with the likes of Lex Fridman and Tim Ferriss saying that life extension is definitely really important to me.

I think I hope to see the concept of seeing your parents and grandparents die just slowly disappear from the public consciousness as a thing that happens over the course of half a century.

Buterin has emphasized his adherence to the moral philosophy of effective altruism. This value, known to transhumanists as the moral urgency of saving lives, is perhaps what motivated his donations of dog coins to both COVID-19 relief in India and life-extension.

Just even the process of aging turning into something that just becomes reversible and it being a regular thing for people to live one and a half, two centuries and then go even further from there, Buterin states.

Pinned in Buterins Twitter is an essay called The Fable of the Dragon Tyrant by professor Nick Bostrom, director of the Future of Humanity Institute. It argues that allowing death from old age is unethical. If you view aging as a disease, the urgency to support the transhumanist project also makes sense.

While we still lack effective and acceptable means for slowing the aging process, we can identify research directions that might lead to the development of such means in the foreseeable future, states Bostrom. The key to freeing humanity from the dragon tyrant of aging, is funding. The new riches from crypto are key.

Bitcoin.com founder Roger Ver has already signed up to be cryogenically frozen. Rather than investing in cryptocurrency stuff, I want to focus on the extreme life extension technologies, because if you die, you cant enjoy your life anymore, Ver told Cointelegraph. Hes so confident in the tech, he even considered being cryogenically frozen as a legitimate alternative to going to prison in 2002.

DAOs are also taking part in this life extension renewal. There is a strong overlap of crypto people and longevity people, Vincent Weisser, core team member at VitaDAO tells Cointelegraph. VitaDAO funds longevity research and exceeded its initial token raise funding target of $490,000 in June 2021.

Now, they are working with popular blockchain crowd-funding platform Gitcoin to include a future funding category for longevity and life extension.

Transhumanist philanthropy and funding at scale holds the potential to significantly impact longevity research and the transhumanist project.

Transhumanism is a loosely defined movement that promotes the use of technology to enhance the human condition. This includes information technology, genetic engineering, and artificial intelligence for radical extension of human lifespan, augmentation of physical and intellectual capacities, space colonization, and super-intelligent machines.

The goal is not just life extension, but more, to the point of becoming superhuman. Although the transhumanist pursuit of post-humanity is often thought of as medical, the gambit of transhumanist technologies includes economic and social institutional design and cultural development.

Like crypto communities, transhumanism is grounded in a vision of evolution and individual freedom of choice. In practice, this leads to a sense of personal responsibility for contributing to solutions, such as biohacking or making provisions for being cryogenically frozen and one day hopefully reanimated. The goal of the transhumanist project for society is one based on freedom in determining social arrangements, enabled by self-generating systems and spontaneous order. This description of perpetual, open systems is similar to blockchain.

Not everyone thinks eternal life, or the philosophy underpinning it, is a good idea. Political economist Francis Fukuyama calls transhumanism the most dangerous idea in the world and argues it is a strange libertarian movement whose crusaders want nothing less than to liberate the human race from its biological constraints. He lists the risks of the fraught nature of humankind to want to live forever, the effects on equality between the haves and the have nots, and that the essence of humanity is mortality. Yet, transhumanism has a long history in crypto communities.

Transhumanist values are reflected in the ideological underpinnings of blockchain communities around anarchy and autonomy, self-improvement, and a long-term mindset.

Transhumanist ideas have long existed in the technology communities that pioneered the core tenets of public blockchains. For example, cryptography pioneer Ralph Merkle (inventor of public key distribution and Merkle trees) considered himself a transhumanist, publishing on such matters as The Molecular Repair of the Brain.

Furthermore, there was substantial cross-pollination of ideas between the Cypherpunks mailing list, which discussed ideas on privacy and digital cash throughout the 1990s and 2000s in the lead-up to the invention of Bitcoin in 2008, and the Extropian mailing list.

Extropy is the extent of a systems intelligence, information, order, vitality, and capacity for improvement. According to 1998s Principles of Extropy published by president of the Extropy Institute, Max Moore, extropians are those who seek to increase extropy. The core principles, refined in The Extropist Manifesto in 2010, are endless eXtension, meaning perpetual growth and progress in all aspects of human endeavor; transcending the restrictions of authoritarianism, surveillance, or social control; overcoming property rights, including IP and money, by sharing knowledge, culture, and resources; intelligence, including independent thinking and personal responsibility; and smart machines, specifically the attainment of Friendly Artificial Intelligence that exceeds human ability, through funding and favorable legislation.

Extropians advocate and explore the philosophies of transhumanism (technological enhancement), extropy (improving the human condition), and the future. Numerous prominent cypherpunks also subscribed to the Extropian mailing list, including co-founders of the cypherpunk movement Timothy C. May and Eric Hughes.

Another active member of the extropians was Hal Finney. Finney was co-developer of the first anonymous remailer, the first person to transact Bitcoin with Satoshi and the first maintainer of the Bitcoin codebase. He was cryogenically frozen when he passed away in the hope of living in the future alongside his wife, Fran, who noted that Hal liked the present. But he looked towards the future. For this community, technologies like digital cash offered a way of long-term thinking about the future of humanity, transhumanism, and solutions and preventions for cryogenics, outer space, and catastrophic environmental or societal collapse.

The cypherpunks interest in extropianism, and vice versa, was concerned with building infrastructure today that would sustain the future of human evolution. In some ways, this makes sense.

In order for ones cryogenic suspended animation to be paid for, maintained and reversed to wake them up in the far-flung future where science advances to the point where this aspiration is realized, there needs to be an incentive. In 1994, Wired magazine reported over 27 frozen people (technically 17 frozen heads and 10 entire bodies) at the Alcor Life Extension Foundation, the same company that Roger Ver has signed up with.

Immortality is mathematical, not mystical, stated Mike Perry, their overseer. The hope is that Bitcoin will be a resilient long-term incentive for someone to wake up Hal, Fran and other friends. Herein lies the need for long-term blockchain infrastructure, to last as a secure monetary reward until the century when unfreezing is possible.

Among the principles of extropianism set out by Moore is intelligent technology, meaning technologies that bring beneficial results, including genetic engineering, life-extending bio-sciences, intelligence intensifiers, smarter interfaces to swifter computers, neural-computer integration, worldwide data networks, virtual reality, intelligent agents, swift electronic communications, artificial intelligence, neuroscience, neural networks, artificial life, off-planet migration, and molecular nanotechnology.

Expect to see more life extension, brain-machine interfaces, limb regeneration, curing deafness, bionic sight and more incredible feats in the next decade, states Srinivasan. Transhumanists predict an inevitable singularity, when technology becomes intelligent, uncontrollable and irreversible, to occur around 2035. Blockchain is part of this technology stack.

The lofty, futuristic ideas of transhumanists depend on resilience and digital infrastructure. This is especially true for the goal of friendly artificial intelligence, which is seen as an enabling condition for rapid development across all other core principles of the project. Thanks to blockchain technology, and blockchain philanthropy, we are beginning to have the resources to do it.

An immutable worldwide computer enables a decentralized autonomous organization to allow our uploaded brain image to automatically coordinate with friendly artificial intelligence in a decentralized, freedom-loving way.

Blockchains immutability makes it the perfect long-term infrastructure. Cypherpunks were paranoid about Orwellian dystopias in which authorities would rewrite history to match state propaganda. The architectural and political decentralization of public blockchains means that no one can tamper with, control or delete the record of history. This makes it the perfect record-keeping infrastructure if we are going to live forever.

This is essential when it comes to your brain image or your Bitcoin balance. In order to document who owns what coins when you are cryogenically frozen and woken up in the next century, you need resilient, long-term, tamper-proof blockchains. The values of independence and immutability are essential to both crypto enthusiasts and transhumanists. Buterin states:

Its great that we have people trying to upload or improve brain scanning. Its also great that we have people including cryonics, so we could just go to sleep in the freezer and eventually, hopefully, sometime in the future [] anyone who gets cryogenically frozen will be able to wake up.

The combination of transhumanist philosophy, blockchain technology, community obsession and money enable whole new possibilities. The transhumanist-blockchain vision is that we will all be connected, humans and machine intelligence, through decentralized, automatically executing smart contracts and marketplaces.

Blockchains provide a platform infrastructure to enable a host of technologically advanced human-machine futures. One example is a decentralized marketplace for AI, such as SingularityNET by artificial intelligence researcher, transhumanist, and CEO Ben Goertzel. Here, intelligent computational agents buy, sell and barter over work for digital tokens via a blockchain.

In The Transhumanism Handbook, Melanie Swan predicts that crypto cloudminds, in which mind node peers interact through multicurrency pay channels of digital denominations, will algorithmically enforce good behavior between humans and machines through the privacy and transparency of blockchains. According to Srinivasan, this could also lead to cloud cities, which allow their members to negotiate with other jurisdictions and crowdfund territories in the physical world.

Transhumanism, like human beings, is only in its early stages of development.

Transhumanism, with its focus on superhumans and longevity instead of an afterlife, can be viewed as something akin to a religious impulse. Although many transhumanists take their worldview to be in opposition to religious outlooks on life, transhumanism may become the religion of blockchainers. Yet, this doctrine does not come without a clear burden of responsibility.

While some fear transhumanism, a core tenet is to ensure that technology produces positive outcomes for humanity. Transhumanists advocate that the choice to improve human capacities lies with the individual.

Part of the longevity research agenda is figuring out how to measure the risks of friendly artificial intelligence and make it truly friendly to avoid a catastrophe. Transhumanists want to avoid X risk, which is existential risk to humanity of a hypothetical, global, catastrophic future event that could damage human well-being or destroy human civilization. This is why colonizing outer space is so logical, as Elon and other crypto enthusiasts are pursuing. The Extropian Principles, v. 3.0 by Max Moore from 1998 emphasizes this, stating that migration into space will immensely enlarge the energy and resources accessible to our civilization. Of course, smart machines will also help us explore space because they can handle more gravitational force than humans as they enter the orbit of other planets.

To a transhumanist, the goal of technology is to amplify our abilities and extend human freedoms. How could we ensure humanity lives forever and life spreads throughout the universe? asks Weisser from VitaDAO. Its all about probabilities and increasing the probability that humanity will survive, he says.

A long-term mindset treats aging as an engineering problem. Now, it remains to be seen if the intersection of blockchain philanthropy, VitaDAOs research collective, and other decentralized, transhumanist pursuits will be cautiously and collectively propelled forwards with the kind of long-termism that will benefit humanity. As Buterin states:

I hope you guys can [] come to my thousandth birthday party.

Read the rest here:
Crypto leaders are obsessed with life extension. Here's why Cointelegraph Magazine - Cointelegraph

What Does It Mean to Live Forever? – OZY

If 100 is already the new 80, what about living till youre 150 years old? Growing up, my dad, a doctor obsessed with the idea of immortality, would tell how his grandparents back in Lebanon had lived well past the 100-year mark. How? They simply ate well, he used to say, as if their secret was no mystery at all. But back in the mid-19th century, they were the exception to the rule: People generally died much, much earlier.

Today, as humans continue to lust after any number of material and immaterial objects, scientists are researching radical life extension technology like never before. Amazing, right? Lets see. Read on to learn about the great, the weird and the downright costly behind our quest for eternal existence.

Editors note: OZYs all about bringing you the new and the next . . . in fresh ways. Were trying a new look for your favorite newsletter to make your experience even more delicious. Please share your thoughts on the new look below.

Probably. Think about it: 200 years ago, there was no such thing as an active 90-year-old. Fast forward 20 decades, and photos of people breaching the 100-year barrier have become almost routine. Vaccines, antibiotics and a better understanding of what is good for our bodies and minds have taken us far. By 2050, the U.N. estimates there will be 3.7 million centenarians around the world, a major bump from the nearly 600,000 today. How can we push our biological clocks even more, keeping our minds sharp and bodies healthy for longer? One departure is to treat aging as an illness. Thats right. A tribe of scientists, including Steven Austad, a biologist at the University of Alabama, says the key to drastically longer life lies in altering the processes that prevent our very molecules from growing old.

Scientific progress looks promising. Experts have already successfully applied an antifungal used during organ transplants to extend the lives of mice. Just think what that might mean for a human. Thats not all. A string of revolutionary health treatments on the horizon is poised to change how our bodies deal with aging. Heard of a pill that mimics the benefits of exercise? Or drugs that trick our internal clock into thinking its younger? How about nano-robots that find and destroy disease inside our bodies and cell reprogramming? The future of anti-aging medicine is mind-blowing. But dont rush to your doctors office just yet. Despite such theoretical advances, some experts believe our bodies have a built-in expiration date. Not to mention theres a host of issues preventing humans from living longer that must be tackled, starting with poverty, violence, pollution, climate change and traffic accidents.

Can you imagine what you would do if you could live your peak years your 20s and 30s, say over and over? Maybe we use the [extra] years to reimagine the trajectory of life, just like we did 100 years ago, when we invented childhood and retirement, Austad said in a TED Talk. John Davis, a philosophy professor at California State University, Fullerton, brings a similarly philosophical lens to the question. I think people get wiser as they get older, he tells OZY. Given time and life experience, people become more patient, more aware of what a wise choice and a foolish choice looks like, and less violent. So we might find that a society that lives longer is a better society.

Now for the bad news. Increased pressure on already overstretched global health care systems and an inadequate supply of jobs, food and housing are just some of the challenges we face if we were to live for as long as wed like. Longer, healthier lives translate to expanding populations worldwide, a change the planet might not be able to withstand. We are already facing the consequences of overpopulation, Davis says. Its called climate change. The solution there remains controversial and might require something more radical than eternal life.

Outside the lab, futurologists have been putting forth their own takes on life extension. But be warned: you would need deep pockets to access them. Ray Kurzweil, a resident futurist at Google a company currently investing in the study of aging claims that by 2029, medical advances could start adding an additional year, every year, to peoples life expectancy, at least to those who can afford it. Researcher Aubrey de Grey posits that by 2036, many people with access to the right therapies (e.g., working to make our molecules younger) could avoid aging-related diseases or maladies entirely. Is there a catch? Unfortunately, yes. To reach the 150-year-old mark, you might need to live in an environment free of stressors and a wad of cash to cover what will be costly treatments. Tempted by whats being offered by Libella Gene Therapeutics, which claims to reverse aging by up to 20 years? Be prepared to fork over a whopping $1 million.

The price tag may be shocking, and it points to another disturbing truth: Longevity is set to become the new standard-bearer of inequality. And its not strictly a rich-country-versus-poor-country distinction, or even race, which is a major determinant of life expectancy in the U.S. A study by Northwestern University in Illinois found that Americans with a higher net worth at midlife live longer than their poorer counterparts. Even among brothers and sisters, those with greater wealth tend to outlive their siblings. Thats even taking into account identical genetic profiles, meaning the only factor that separates them is money.

Unless, that is, you happen to live in one of the worlds blue zones: a select group of countries in which people have been living longer for reasons unrelated to their bank account. Take Nicoya, for example. Centenarians in this lush Costa Rican peninsula say their secret to a long life is robust social networks and strong family ties. On the other side of the world, Japans super-senior citizens claim that healthy diets and exercise have paved the way to a lengthy and happy existence. Even if Kane Tanaka, the worlds oldest person at 118, admits she loves chocolate and soda. Money, however, can play a role. Just look at Monaco, the uber-wealthy principality where residents live on average to nearly 90 years old.

Dont live in any of those places? Dont despair. Someday there may be another option for those who want to live a lot, lot longer: Upload your consciousness, Black Mirror style. While we are still far from transferring our minds onto a chip, Artificial Intelligence advances could make this sci-fi-sounding proposition a reality. Some people have already signed on to a program to freeze their brains and bodies in liquid nitrogen coffins to preserve the essential parts of their personalities. Cryonics preserves the body until science has progressed to a point where a person could be reanimated and cured of whatever diseases they suffered from. In 2016, a 14-year-old girl with a rare form of cancer won the right to be cryogenically frozen after she died, in the hopes shell be brought back to life once a cure for her disease is discovered.

Yeah, we all know this one. Harvard researchers have found that increasing the amount of red meat you consume may, in some cases, raise the risk of early death. Participants in the experiment who increased their meat consumption by just half a serving per day (around 1.7 ounces) over eight years had a 10% higher risk of dying over the subsequent eight-year period. The studys authors also claim a significant benefit to replacing a portion of your weekly meals with non-meat options. Its not just good for you, its good for the planet. But Jeralean Talley, who lived to 116, might prove the authors wrong. This American super senior told Time in 2013 that one of the secrets to her longevity is a pork-rich diet, especially pigs ears and feet.

Walking an extra 1,000 steps a day could increase your chances of living a long life, according to the American Heart Association. The benefits of incorporating walking into your daily routine were consistent across people who took one long stroll and those who opted for shorter bursts throughout the day. That included going shopping or walking to your car. Heading out for a walk should be a priority for everyone, especially now that remote work is forcing many to park their butts for long stretches. Each increase of 1,000 steps was linked to a 28% decrease in the risk of early death.

When American Loreen Dinwiddie died in 2012 at age 109, she was the worlds oldest vegan. She credited her diet for helping her reach that milestone and for giving her a pep in her step. Its well-known that eating greens keeps you healthy day to day, but it also helps you live longer. Consuming five servings of fruits and veg every day translates to a 13% lower risk of early death. But dont despair, some fun is also allowed. Misao Okawa, the oldest person on the planet before she passed away in 2015 at age 117, said the secret to her long life was simple: eating delicious things including sushi and noodles.

You keep me young isnt just a sweet phrase. A study by researchers at the Boston University School of Medicine in 2014 found that late motherhood can lead to a longer life for women who delivered their last child after 33. In fact, they are twice as likely to live to 95 than those who had their last kid by 29. Furthermore, the New England Centenarian Study, published in 2014, concluded that women who bore children after turning 40 were four times more likely than younger mothers to reach 100 years old. Theres a caveat, though: Just delaying pregnancy wont make you live longer; growing old depends on your genes too. Read more here.

See the original post here:
What Does It Mean to Live Forever? - OZY

Monsters of Rock: Newcrest approves life extension at Telfer as Havieron awaits – Stockhead

Newcrest Mining (ASX:NCM) will pump 246 million big ones into a fifth cutback at Telfers West Dome deposit in a bid to extend the life of the ~30 million ounce WA gold mine.

Newcrest will add two years to the Telfer schedule and prepare for the introduction of the higher grade 3.4Moz Havieron gold-copper project in 2023.

The Paterson province ore body, a 60-40 joint venture between Newcrest and London-listed explorer Greatland Gold, electrified the junior end of the market when it was found back in 2018.

Havieron and Rio Tintos Winu copper mine, which will enter production around 2025, have reinvigorated interest in the gold and copper district wedged between WAs resource rich Goldfields and Pilbara regions.

Newcrest produced 416,138oz of gold and 13,177t of copper at Telfer in the 2021 financial year and saw costs fall to around US$1203/oz in the June quarter at an operating margin of US$577/oz.

Thats decent from a mine once so marginal its threatened closure was central to lobbying by gold miners to avoid a royalty rate hike from the WA Government back in 2017.

This cutback is an investment in Telfers future which will ensure the operation is able to continue for at least the next two years, Newcrest boss Sandeep Biswas said. With additional drilling, we believe there is the potential for further mine life extensions in the open pit and the underground beyond this time.

With the excellent progress we are making at the nearby Havieron project, our objective is to continue utilising the Telfer plant without interruption as we look to introduce Havieron and other new potential feed sources in the future.

There is of course no shortage of juniors drilling away in the Paterson province who could be in line for a Newcrest payday if they find anything of interest.

RBC mining analyst Kaan Peker said the announcement was a sign of confidence in Havieron, which RBC values at $800 million for Newcrests 60 per cent stake.

The capital being spent on the cut-back at Telfer is significant given mine life, but we believe this opens up long-term optionality with Havieron and potential mine-life extension for West Dome, he said in a note. The announcement today flags NCMs confidence in Havieron.

The broader materials sector was dragged down by a massive decline from Rio (ASX:RIO), which lost almost 7% of its value or almost $9.

Iron ore prices rose slightly to halt a major slide in recent days, but Rio went ex-dividend on its record $7.60 a share payout and fell correspondingly.

It has also suffered some damaging PR in the past couple days after a review commissioned by Rio Tintos partners into a delayed expansion of the Oyu Tolgoi mine in Mongolia blamed Rios alleged mismanagement for a US$1.45 billion blow out.

Strong copper prices in the first half of 2021 are likely to give a nice sheen to OZ Minerals half year results, which come out next Wednesday.

$7.7 billion capped OZ is up more than 20% year to date and almost 70% over the past 12 months.

Strong results across the first half of the year, in particular at the Prominent Hill copper-gold mine in South Australia prompted OZ to up guidance for 2021 last month along with the release of its June quarterly.

The miner expects to produce 120,000-145,000t of copper and 205,000-228,000oz of gold at AISC of US$1.30-1.45/lb in 2021.

The major coal stocks on the ASX continue to impress, with Yancoal and Coronado both retracing their early 2021 losses in recent months on the back of higher coking and thermal coal prices.

Chinese-backed Australian coal producer Yancoal is up a tidy 20-odd per cent over the past week, while Coronado has made similar gains despite posting a $96 million loss over the first half of 2021.

Get the latest Stockhead news delivered free to your inbox.

It's free. Unsubscribe whenever you want.

You might be interested in

Follow this link:
Monsters of Rock: Newcrest approves life extension at Telfer as Havieron awaits - Stockhead

Leading longevity researcher accused of sexual harassment – FierceBiotech

Until this week, Aubrey de Grey was best known as the longevity researcher who predicted the first human to live 1,000 years may already be alive. Now, de Grey stands accused of being a sexual predator.

Celine Halioua, who received research funding from de Greys SENS Research Foundation, set out her accusations in a blog post titled Aubrey de Grey is a sexual predator. Laura Deming, founder of life extension VC shop The Longevity Fund, set out separate allegations against de Grey in her own blog post.

Deming wrote: I had one bad experience with him when I was 17he told me in writing that he had an adventurous love life and that it had always felt quite jarring not to let conversations with me stray in that direction given that [he] could treat [me] as an equal on every other level. He sent this from his work email, and Id known him since I was 14.

At the time, Deming said she wrote it off as a mistake. However, in the past few months, in part through conversations with Celine Halioua, Deming has come to believe her experience is part of a serial pattern hes enacted with women over whom hes in a position of power.

The accusations made by Halioua center on a dinner at which she was sat next to de Grey by a SENS executive. I was told to keep him entertained; Aubrey funneled me alcohol and hit on me the entire night. He told me that I was a glorious woman and that as a glorious woman I had a responsibility to have sex with the SENS donors in attendance so they would give money to him, Halioua wrote.

Halioua left that dinner sobbing and said it has taken her years to shake the deep-seated belief that I only got to where I am due to older men wanting to have sex with me. In the post, Halioua accused an unnamed SENS executive of harassing her so severely that she eventually dropped out of my PhD to escape him. Halioua is now CEO of a biotech startup developing drugs to extend dog life span.

De Grey responded to the accusations in a Facebook post. The longevity researcher admitted he inadvisedly wrote the email discussed by Deming and unreservedly regrets having done so. In all other regards, de Grey denies the accusations, which he framed as a setup.

I'm putting it out there right now: if other accusers come forward with supporting evidence, I will step aside a great deal faster than Cuomo just did. But if they don't who's the real culprit here? Hint: in my ever-so-personal view, it's not Celine or Laura. The unequivocally clear conclusion that I draw from the above is that they have been set up, de Grey wrote.

De Grey believes people have deceived Deming and Halioua into the view that I have done many things that I have in fact not done. As to who would orchestrate such a deception and why, de Grey said: I have been vigorously advised to keep my counsel on that question for another day or two but, as they say, watch this space.

SENS has put de Grey on administrative leave. An independent investigation into the allegations, which SENS first learned of in late June, is now underway.

Read more:
Leading longevity researcher accused of sexual harassment - FierceBiotech

How will the Pentagon close the homeland missile defense gap? – DefenseNews.com

WASHINGTON The U.S. Missile Defense Agency is examining the possibility of building a layered ballistic missile defense architecture for the homeland that would bolster the current ground-based system in Alaska, all while a next-generation capability is developed and fielded.

The MDA featured its plan in its fiscal 2021 budget request, but there isnt much of a strategy laid out in its fiscal 2022 funding picture. And so lawmakers want answers before turning on the funding spigot.

Developing such an architecture, even though it would use mostly proven systems, has many hurdles, as MDA Director Vice Adm. Jon Hill said last year.

The plan would include establishing layers of defensive capability relying on the Aegis Weapon System, particularly the SM-3 Block IIA missiles used in the system, and a possible Aegis Ashore system in Hawaii. The underlay would also include the Terminal High Altitude Area Defense system.

The layered approach would buy time while the Pentagon scrambles to field a new interceptor to replace older Ground-Based Interceptors after canceling its effort to redesign the kill vehicle for the GBIs in its Ground-based Midcourse Defense system located at Fort Greely, Alaska, and Vandenberg Space Force Base, California.

The test stressed the system, putting it up against a long-range intercontinental ballistic missile, but the MDA wants to conduct another yet-to-be-scheduled test against a more complex ICBM target with separation debris and countermeasures.

However, the validation of a possible underlay doesnt stop with a few tests. Upgrades will be required based on threats; combat system certifications will need to be conducted; and work must be performed with the Navy to determine where Aegis ships should deploy, Hill said. The agency will also have to determine how quickly it can ramp up its production line for SM-3 Block IIA missiles.

Sign up for our Early Bird Brief Get the defense industry's most comprehensive news and information straight to your inbox

Subscribe

Enter a valid email address (please select a country) United States United Kingdom Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D'ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe

Thanks for signing up!

By giving us your email, you are opting in to the Early Bird Brief.

Hill said last fall that if the agency succeeds with Aegis, it could go down the path with THAAD, then work on engagement coordination between layers.

When the FY22 budget request came out at the end of May, Hill said funding would focus on looking at how the Command and Control, Battle Management, and Communications system could incorporate Aegis and THAAD capabilities for the homeland, and how those systems would be linked to give options to combatant commanders.

But, he added, those decision have not been made to date.

When asked if the agency was cooling on a layered homeland defense, Hill said: I wouldnt say its no longer a priority since we do have investment in the budget, but there are some very serious policy implications, and so we want to make sure that we get the policy angles right.

The agency also wants to make sure its still a need for U.S. Northern Command in light of a now-established service life extension program for the GMDs Ground-Based Interceptors already emplaced, Hill noted. The command did not include layered homeland defense in its list of unfunded requirements sent to Congress in June.

The big concern, back when layered homeland defense was first discussed, was the concern that the existing fleet would start to lose its reliability over time while we also had this timeline for the Next-Generation Interceptor off to the right, Hill said.

Plans for the Next-Generation Interceptor are moving forward with a competition between Lockheed Martin and Northrop Grumman, and theres talk the timeline for first emplacement could be earlier than anticipated.

Yet, Congress is getting impatient over a lack of answers regarding progress toward an architecture that could shore up any gap in capability now and into the future.

During a June 14 hearing with the House Armed Services Committees strategic forces subpanel, Rep. Elise Stefanik, R-N.Y., asked for an update on the report on the layered homeland defense system, which was required in the FY21 National Defense Authorization Act. She noted that the deadline of March 1, 2021, had passed.

Hill responded that, while there are no technical barriers to an underlay, its really a policy question that we need to come through.

Without offering a timeline for delivering a report to Congress, Leonor Tomero, the Pentagons assistant secretary of defense for nuclear and missile defense policy, said at the same hearing: I can assure you that we are looking at what investments we make for a layered homeland defense, what priorities are the subject of studies again in consultation with the Missile Defense Agency and the Office of Cost Assessment and Program Evaluation.

The Defense Department made an initial investment in FY22, Tomero added, and studies will inform further investments in FY23.

The Strategic Forces Subcommittee followed up in its markup of the FY22 authorization bill with a renewed push for a detailed report. The committee would direct the Pentagon to submit a report by the end of 2021 on development and deployment plans for using Aegis with SM-3 Block IIA interceptors as part of a layered missile defense system.

The report should include how Fort Drum, New York, previously identified as an East Coast location for Ground-Based Interceptors, might be used for future layered defense. Stefaniks district includes Fort Drum.

An analysis of how deploying Arleigh Burke-class guided-missile destroyers for homeland defense would affect Navy readiness and global force management would also be required, and the report should contain an applicable manning strategy should land-based Aegis systems be deployed as part of the architecture.

The House Appropriations Committees defense subpanel, in its markup of the FY22 spending bill, took hacks at Defense Department funding applied to the layered homeland defense totaling $203.7 million.

The committee zeroed out Aegis BMD layered homeland missile defense development, cutting all $98.96 million for which the MDA had budgeted, and a total of $64.56 million to work on similar development for THAAD.

According to the MDAs FY22 budget justification documents, the plan for developing Aegis for homeland defense includes refining system-level requirements and development to expand threat and mission space and to increase performance against moderate threats.

The committee noted the funding cut is due to a lack of validated requirements and acquisition strategy.

The Senate Armed Services Committee released a summary of its FY22 authorization bill, but aside from supporting the MDAs pursuit of the NGI, there is nothing else signaling its intentions.

The Senate Appropriations Committees defense subpanel has yet to release its markup of the FY22 spending bill as of press time on Aug. 2.

Software and hardware improvements needed to evolve both THAAD and Aegis systems, will be important to proceed irrespective of whether or not they end up deployed to support a thick defense of the continental United States, Tom Karako, senior fellow with the International Security Program and the direct of the Missile Defense Project at the Center for Strategic and International Studies told Defense News.

The non-recurring engineering planned for the layered defense program elements would be very useful to complete to support regional applications, he added. These systems began as regional defenses, and their continued evolution will benefit regional protection, such as for bases in Guam, Japan, and the like.

See the original post here:
How will the Pentagon close the homeland missile defense gap? - DefenseNews.com

Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., MBA – StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (Amunix), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers and cytokine therapies for patients with cancer, today announced the appointment of Ciara Kennedy, Ph.D., M.B.A. to its board of directors. Dr. Kennedy brings to Amunix a wealth of strategic and operational experience across multiple therapeutic areas and stages of development in the biopharmaceutical industry.

We are excited to welcome Ciara, a leader in the biotech industry, to Amunix, said Angie You, chief executive officer of Amunix. Ciaras strategic, transactional and operational expertise will be invaluable as we plan to initiate a Phase 1/2 clinical trial for our lead program AMX-818, a masked HER2-targeted T cell engager, in early 2022 and transition into a clinical stage company. In addition, her visionary leadership will contribute to our strategic focus of building out our pipeline of masked T cell engagers and cytokines.

Dr. Kennedy added, I am delighted to join Amunixs board and am excited about the potential of its proprietary Pro-XTEN technology to harness the untapped potential of T-cell engagers and cytokines. I look forward to working closely with the experienced team as the company matures and grows its pipeline of promising therapeutics that has the potential to change the landscape of potent options for solid tumors.

Most recently, Dr. Kennedy was the President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a clinical-stage company developing innovative drug therapies for debilitating and life-threatening diseases in patients with compromised immune systems, where she led the company through a successful acquisition by Pfizer Inc. Prior to Amplyx, she was chief operating officer of Lumena Pharmaceuticals Inc. where she oversaw operations including clinical development and helped lead its successful acquisition by Shire plc. Earlier in her career, Dr. Kennedy also held various roles at Cypress Bioscience, Inc. and Biogen Idec Ltd.. Dr. Kennedy has a strong track record of building companies through to later stages of clinical development with a unique breadth of experience across business development, finance, program management, and clinical/regulatory strategy.

In addition to Amunix, Dr. Kennedy is on the boards of Otonomy, Inc. and Aristea Therapeutics, Inc. She holds a Ph.D. from Queens University of Belfast, Northern Ireland and an M.B.A. from the Rady School of Management University of California, San Diego and B.S. from University of Cork, Ireland.

About Amunixs Pro-XTEN Technology

Amunixs Pro-XTEN technology aims to mitigate the toxicity of T cell engagers (TCEs) and cytokines by creating drugs that are preferentially activated in the tumor microenvironment, thus driving tumor cell killing while minimizing on-target, off-tumor toxicity that can damage healthy tissues and/or cause cytokine release syndrome. Amunixs Pro-XTEN technology leverages the intrinsically high protease activity in the tumor microenvironment to preferentially unmask and activate our drugs in the tumor microenvironment. The two proprietary components of this technology are as follows: 1) an XTEN Mask, a polypeptide that serves a dual purpose of acting as a universal spatial shield mask and providing half-life extension, and 2) a protease-cleavable linker which enables preferential unmasking and drug activation in the tumor microenvironment.

About Amunix Pharmaceuticals

Amunix Pharmaceuticals, based in South San Francisco, California, is an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers and cytokine therapies for patients with cancer. Amunix aims to expand the therapeutic index of TCEs and cytokines, which have demonstrated anti-tumor clinical activity, but have not realized their potential due to dose-limiting on-target, off-tumor toxicity. Amunix addresses this challenge by using its universal, protease-releasable masking technology, or Pro-XTEN, to create next generation, conditionally active T cell engagers, or XPATs, and cytokines, or XPACs, that are preferentially activated in tumors as compared to healthy tissues. Amunixs most advanced product candidate, AMX-818, is a masked HER2-targeted TCE for the treatment of HER2-expressing solid tumors, which is currently in IND-enabling studies. Along with other T cell engager programs, Amunix is also applying its proprietary masking technology to its first masked, protease-activated cytokine program, IL12-XPAC, which is in discovery stage.

For additional information about the company, please visit http://www.amunix.com.

Contacts

Company Contact:Jen Herbach Director, Corporate DevelopmentBD@amunix.com

Media Contact:Sylvia Wheelermedia@amunix.com

Investor Contact:Zeeshan MerchantChief Financial Officerinvestors@amunix.com

Link:
Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., MBA - StreetInsider.com

Navigo Proteins and MDimune Enter into a Research Collaboration on Affilin-Mediated Targeting of Extracellular Vesicles – BioSpace

Solid tumor-specific scaffold protein ligands from Navigo combined with MDimunes BioDrone technology to create novel targeted extracellular vesicle-based therapeutics

Halle/Saale, Germany and Seoul, Korea, May 11th, 2021. Navigo Proteins, a protein engineering biotech company generating scaffold protein-based affinity ligands, and MDimune, a biotech company developing an innovative drug delivery platform based on exosome-like, nanosized cell-derived vesicles (CDVs), today announced a technology collaboration to achieve tissue-targeting of extracellular vesicles (EVs). The ongoing research combines Navigos target-binding Affilin molecules with MDimunes CDV technology, to enable Affilin-mediated delivery of CDVs specifically to solid tumor targets.

For the current collaboration, Navigo Proteins will contribute its existing solid tumor-specific Affilin molecules to decorate the surface of the exosome-like CDVs from MDimunes BioDrone technology, thereby pioneering next-generation, targeted extracellular vesicle-based therapeutics (See Figure 1).

Figure 1: Affilin-mediated tumor targeting of CDVs

Dr. Ulrich Haupts, Chief Scientific Officer of Navigo Proteins commented: We are looking forward to combining our selectivity-conferring Affilin molecules with MDimunes extracellular vesicles manufacturing platform, since this opens up an exciting new application for our scaffold protein-based Affilin molecules in the upcoming field of exosome-based therapeutics. The modular and highly engineerable Affilin technology can be a very attractive solution for the precise, targeted delivery of exosome-like vesicles, carrying different payloads to different target tissues.

Recently, we have invested significant efforts and resources to expedite effective steering of our vesicles, CDVs, to tumors or other resistant tissues. The current collaboration with Navigo Proteins is one of them highlighting our recent focus. Navigo Proteins demonstrated expertise in generating highly tissue-specific ligands will be key to enable this goal and ultimately build a foundation for our BioDrone platform technology, said Dr. Seung Wook Oh, Chief Scientific Officer of MDimune.

Affilin Affinity Ligands

Navigos Affilin molecules are target-specific, small, stable, highly engineerable, single-chain affinity ligands and are based on human Ubiquitin as a protein scaffold. Since Ubiquitin is an evolutionarily conserved natural human protein, also present in plasma, Affilin molecules have low immunogenic potential in humans and can also be directly used in various pre-clinical animal models.

Affilin molecules are currently being developed as antibody-alternatives in protein-drug conjugates, radio conjugates, CAR-T cell therapy, and as bi/multi-specific molecules by combining them with antibodies. With this collaboration, Navigo aims to extend the applicability of Affilin molecules to direct exosomes and extracellular vesicles to the target tissues of interest.

BioDrone Platform Technology

MDimunes BioDrone platform facilitates the production of CDVs, exosome-like, nanosized vesicles, in large quantities from various cell types by a proprietary extrusion method. CDVs are similar to exosomes in size, properties, and functions, but exhibit substantial advantages in yield that is more suitable for large-scale production and versatility to allow highly sophisticated engineering, starting from virtually any cell type. BioDrone technology is emerging as a highly versatile and scalable delivery system to address many human diseases, including cancer, neurodegeneration, and more.

While the current project is aimed at Affilin-CDV-mediated payload delivery to solid tumors, this technological advance will not only be limited to cancer but could be expanded to other tissues and diseases.

About Navigo Proteins GmbH

Navigo Proteins is a premier protein engineering company developing affinity ligands, based on its proprietary platform of selected, small, and stable, yet highly engineerable scaffold proteins. These ligands serve as target-binding proteins in biotherapeutic molecules (PRECISION TARGETING) or for commercial custom affinity purification of biologics (PRECISION CAPTURING).

Navigos PRECISION TARGETING unit creates proprietary Affilin molecules based on the human Ubiquitin scaffold a highly conserved, small (8.5kDa) and stable natural human protein. A major strength of the Precision Targeting toolbox is its modular engineerability. The target-specific Affilin molecules can be combined with a variety of carrier units for site-specific payload coupling as well as half-life extension moieties and function-conferring effector modules to convert them into different biopharmaceutical modalities. Navigos ligands are currently being developed as Affilin-drug conjugates, Affilin-radio conjugates, Affilin CAR-T cell therapy and can also be fused to antibodies to create robustly-to-produce bi-/multi-specific molecules (MabfilinTM/FabfilinTM).

For more information visit https://www.navigo-proteins.com/ and follow Navigo Proteins on LinkedIn.

About MDimune Inc.

MDimune, a South Korean biotech founded in 2015, has been committed to the development and implementation of state-of-the-art BioDrone platform technology. BioDrone is an innovative technology that relies on human-sourced CDVs, nanosized vesicles obtained from various cells by using a proprietary extrusion method to achieve target-specific drug delivery. With superior productivity compared to exosomes, BioDrone is emerging as a highly versatile and scalable delivery system to combat diverse debilitating human diseases, including cancer, neurodegeneration, and rare diseases.

MDimune is expanding its global network to harness effective tissue targeting strategies to achieve highly tissue-specific delivery of various cargos such as miRNA, siRNA, mRNA, and proteins. The company envisions applying this novel BioDrone platform to address various needs of pharmaceutical clients who are looking for effective drug carriers.

For more information visit http://www.mdimune.com/en/.

Navigo Proteins Contact

Dr. Oliver Schub

Director Business Development

oliver.schub@navigo-proteins.com

Tel.: +49 (0)345 27996330

MDimune Contact

Brin Choi

Manager, Business Development

jychoi@mdimune.com

Tel.: +82 (0)70+7826

Go here to read the rest:
Navigo Proteins and MDimune Enter into a Research Collaboration on Affilin-Mediated Targeting of Extracellular Vesicles - BioSpace

Global Nuclear Plant Life Extension Market Insights 2021 Industry Overview, Competitive Players & Forecast 2027| Areva,CNNC,Rosatom,Westinghouse…

May 9, 2021 (Reports and Markets) Nuclear Plant Life Extension Market

Reports And Markets recently added a research report on the Nuclear Plant Life Extension Market, which represents a study for the period from 2021 to 2027. The research study provides a near look at the market scenario and dynamics impacting its growth. This report highlights the crucial developments along with other events happening in the market which are marking the growth and opening doors for future growth in the coming years. Additionally, the report is built on the basis of the macro- and micro-economic factors and historical data that can influence the growth.

The report offers valuable insight into the Nuclear Plant Life Extension Market progress and approaches related to the Nuclear Plant Life Extension market with an analysis of each region. The report goes on to talk about the dominant aspects of the market and examine each segment.

Key Players: Areva,CNNC,Rosatom,Westinghouse Electric Company,CGN,Hitachi GE Nuclear Energy,Mitsubishi Heavy Industries,KHNP,Kansai Electric Power,Japan Atomic Power,Alstom,Hitachi

Get a Free Sample @ https://www.reportsandmarkets.com/sample-request/global-nuclear-plant-life-extension-market-size-status-and-forecast-2020-2026?utm_source=beveragemanager&utm_medium=60

The global Nuclear Plant Life Extension Market segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Nuclear Plant Life Extension market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2021-2027.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Key Points of the Geographical Analysis:

Data and information related to the consumption rate in each region

The estimated increase in the consumption rate

The expected growth rate of the regional markets

Proposed growth of the market share of each region

Geographical contribution to market revenue

Research objectives:

To study and analyze the global Nuclear Plant Life Extension Market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2027.

To understand the structure of the Nuclear Plant Life Extension Market by identifying its various sub segments.

Focuses on the key global Nuclear Plant Life Extension players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Nuclear Plant Life Extension with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Nuclear Plant Life Extension sub markets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

Table of Contents: Nuclear Plant Life Extension Market

Chapter 1: Overview of Nuclear Plant Life Extension Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Get complete Report: https://www.reportsandmarkets.com/enquiry/global-nuclear-plant-life-extension-market-size-status-and-forecast-2020-2026?utm_source=beveragemanager&utm_medium=60

Key questions answered in this report

What will the market size be in 2027 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read more:
Global Nuclear Plant Life Extension Market Insights 2021 Industry Overview, Competitive Players & Forecast 2027| Areva,CNNC,Rosatom,Westinghouse...

Intesa Sanpaolo S p A : supports the development of the Campus Bio-Medico University of Rome with a loan of 50 million euro. The project features…

PRESS RELEASE

INTESA SANPAOLO SUPPORTS THE DEVELOPMENT OF THE CAMPUS BIO-MEDICO UNIVERSITY OF ROME WITH A LOAN OF 50 MILLION EURO. THE PROJECT FEATURES INNOVATIVE SUSTAINABILITY CHARACTERISTICS

Milan, 13 May 2021 - Intesa Sanpaolo and Campus Bio-Medico S.p.A., the organizations set up to promote the Campus Bio-Medico University of Rome, have signed a 50 million euro loan agreement for investments with innovative sustainability characteristics.

The financed investment plan involves the creation of new spaces and infrastructures for university education, training and scientific research all with characteristics of environmental sustainability and energy efficiency.

For Intesa Sanpaolo, this marks the conclusion of one more transaction that is part of the 6- billion-euro earmarked for the circular economy as envisaged by the 2018-2021 Business Plan. 200 Projects have already received funding within this context. The transaction was concluded by the Intesa Sanpaolo IMI Corporate and Investment Banking Division, headed by Mauro Micillo with the support of the Intesa Sanpaolo Innovation Center Circular Economy Desk, the company of the Group dedicated to innovating and spreading the circular economy.

"Supporting Italian excellence such as the Campus Bio-Medico University of Rome in its development projects gives Intesa Sanpaolo great pride and satisfaction," said Richard Zatta, Head of Global Corporate of the IMI Corporate & Investment Banking Division of Intesa Sanpaolo. At a time like the present, which is profoundly marked by the effects of the pandemic, providing support to the healthcare sector, universities and scientific research is even more crucial. The funded project will further expand the areas for university education with eco-sustainable and low environmental impact structures".

"A great crisis like the current one has uncovered how fragile our socio-economic system is, but it has also revealed the great opportunities for universities, as they find themselves spearheading the change towards greater technological, social, scientific knowledge and reflection on the fundamental values of our civic life, social organisation and commitment to the service of others - stated Giuseppe Garofano, Chairman of Campus Bio-MedicoSpA

The transaction includes a tranche of around 30 million euro for the creation of green and mobility infrastructures and innovative spaces dedicated to university education, informal learning and campus life that will host university students as early as the 2022-23 academic year. The project envisages a significant improvement in energy efficiency both in new spaces and in the various related systems, which will make it possible to optimise solar radiation, regulate air renewal and also produce the heat required for heating, thus avoiding the use of natural gas.

A second tranche of 20 million euro will be used to extend the maturity and thus refinance the remainder of a previous mortgage granted to allow the construction of the hospital and university complex which today constitutes one of the country's medical, scientific and academic centres of excellence.

The Campus Bio-Medico University is composed of the Department of Medicine and Surgery (with degree courses in Italian and English, and 24 specialised schools), the Department of Engineering (offering the Chemical Engineering for Sustainable Development course, among others) and the Department of Science and Technology for humans and the environment (with a course specifically focused on the circular economy) attended by over 2,200 students. Its research laboratories host 50 research units, with around 400 researchers.

The Campus Bio-Medico University Hospital has 400 beds, 18 operating rooms, 70 outpatient clinics and a first-level emergency room (currently reconverted into a Covid Center with 100 dedicated beds). It is equipped with all the latest technological equipment for diagnosis and treatment.

To boost and support the Circular and Green Economy, Intesa Sanpaolo has developed a wide and diversified range of financing and advisory products, dedicated to all types of customers, in Italy and abroad. Projects receiving Intesa Sanpaolo loans for the circular economy must meet a number of criteria, including product life extension, renewable energy, resource

optimisation, recyclable products and technologies that enable and foster this economic model. This allows the Bank to disburse loans at increasingly advantageous terms for customers, subject to verifying the achievement of the circular economy objectives.

***

Press information

Intesa Sanpaolo

Media Relations, Corporate & Investment Banking and Governance Areas stampa@intesasanpaolo.com https://group.intesasanpaolo.com/it/sala-stampa/news

Intesa Sanpaolo

Intesa Sanpaolo is the leading Bank in Italy and one of the soundest and most profitable banks in Europe. It offers commercial, corporate investment banking, asset management and insurance services. The Intesa Sanpaolo Group has approximately 14.7 million customers in Italy who are assisted through both digital and traditional channels. It also has

7.1 million international customers which it serves through its commercial banking subsidiaries present in 12 countries in Central-Eastern Europe, the Middle East and North Africa, and through an international network dedicated to corporate customers in 26 countries. Intesa Sanpaolo is considered one of the most sustainable banks in the world. For the Group, creating value means being a driver for growth, for the benefit of both society and the economy. As regards the environment, the Group has set up a 6-billion-euro fund for the circular economy. Intesa Sanpaolo supports major economic inclusion and poverty reduction projects, including an impact fund of 1.5 billion euro for loans available to social groups who struggle to access credit. Intesa Sanpaolo has a high level of involvement in cultural initiatives, organised by the Bank or in collaboration with other entities in Italy and further afield. These include permanent and temporary exhibitions showcasing the Bank's impressive artistic heritage at the Gallerie d'Italia, the Group's museums located in Milan, Naples, Vicenza and soon Turin.

Website: group.intesasanpaolo.com | News: https://group.intesasanpaolo.com/it/sala-stampa/news | Twitter:

@intesasanpaolo | Facebook: @intesasanpaolo | LinkedIn: https://www.linkedin.com/company/intesa-sanpaolo |

Instagram: @intesasanpaolo

Press information

Campus Bio-Medico SpA

Executive Director Domenico Mastrolitto info@cbm-spa.it

Media Relations Manager info@italcommunications.it https://italcommunications.it

Campus Bio-Medico SpA

Campus Bio-Medico S.p.A. is one of the two promoters of the Campus Bio-Medico University of Rome and the company that owns the university campus building and the land on which it is situated. It manages a 90,000 square metre building complex, which includes the 400-bed university hospital and 90 hectares of land, part of which is located within the Decima Malafede Natural Reserve in Rome. Campus Bio-Medico SpA ensures that the institutional goals of the University are pursued and handles the development of new projects for university growth, including through its own managerial and business resources. Its shareholders are non-profit entities, entrepreneurs and private and institutional investors. The university promoters are the Campus Bio-Medico Association and Campus Bio-Medico SpA. They guarantee the pursuit of the institutional aims set out in the Articles of Association and in the Charter of Purposes of the Campus Bio-Medico University of Rome, including through the appointment of some members of the university Board of Directors.

Website: campusbiomedicospa.it - futureunicampus.co m - unicampus.it | News: https://campusbiomedicospa .it/cbm-

media - https://unicampus.it/news-blog | LinkedIn: https://www.linkedin.com/company/campusbiomedicospa

Disclaimer

Intesa Sanpaolo S.p.A. published this content on 13 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 May 2021 10:23:07 UTC.

Read this article:
Intesa Sanpaolo S p A : supports the development of the Campus Bio-Medico University of Rome with a loan of 50 million euro. The project features...

The sun shines for Wirsol Energy: guidance on the circumstances in which waiver can be given in a commercial contract – Lexology

Mr Justice Henshaw handed down judgment on 14 April 2021 in Toucan Energy Holdings Ltd v Wirsol Energy Ltd [2021] EWHC 895 (Comm), a substantive dispute begun in 2018 regarding the construction and sale of 19 solar parks located throughout Great Britain and Northern Ireland.

Wirsol has very successfully defended allegations that it designed and constructed the solar parks defectively, which was said to have caused Toucan significant losses and to require effectively a total re-construction of many of the sites due to allegedly fundamental faults risking catastrophic failures.

Wirsol contended that the solar parks were properly built (save for minor issues) and that Toucans losses were minimal. Wirsol also counterclaimed for approximately 6.5 million in unpaid fees arising out of a contract to procure asset life extensions for the solar parks. Toucan denied that the asset life extension invoice was payable, including on the basis that a necessary condition subsequent to payment had not been satisfied or waived.

Toucans total claim amounted to some 30 million in damages, including a significant sum for diminution in value of the solar parks due to ongoing blight in addition to the remedial/replacement costs it said would be incurred, along with lost revenue from under-performance of the solar parks and claims for liquidated damages.

A five-week trial took place in person at the Rolls Building through October and November 2020, with experts in the fields of electrical engineering, solar asset valuation, quantity surveying and transformer design.

Mr Justice Henshaw dismissed the vast majority of Toucans 30 million claim, finding that only a fraction of the losses relating to alleged defects were made out. Toucans claims for the alleged blight and consequential losses arising from refinancing of its debts were entirely dismissed.

The Judge upheld Wirsols counterclaim on almost all issues, finding that c.6.25m was due for the asset life extensions. The judgment contains a detailed discussion of the circumstances in which a waiver can be given under a commercial contract. The Judge ultimately concluded that Toucan was obliged to give a waiver under the contract in certain circumstances, and that it had done so. In any event, Toucans conduct was such that (if required) it would have been found to have given an equitable waiver.

The case also attracted national press attention after it emerged that Toucan had raised very substantial sums from a local authority to refinance its investments (see, for example, here).

Read the original here:
The sun shines for Wirsol Energy: guidance on the circumstances in which waiver can be given in a commercial contract - Lexology

The age of information Aerospace Manufacturing – Aerospace Manufacturing

Solid State Disks specialises in the design and manufacture of advanced flash data storage systems

In a Q&A session, Solid State Disks sales director, James Hilken looks at the latest trends and demands surrounding the areas of memory and storage and what the sector needs to consider when designing and developing new systems.

As part of the Reactive Group, Solid State Disks (SSD) delivers innovative system solutions to defence, commercial and industrial customers worldwide, and specialises in the design, development and integration of advanced flash data storage systems. The company is also UK flash memory distributors of SanDisk, Innodisk, APRO, Transcend and Smart Modular.

Q) Why is it important to record vast amounts of data and what advantages does it offer to sub-system manufacturers and technology users on the front line?

James Hilken, sales director of Solid State Disks

Operators use such systems to plan and measure mission success, acquire data, develop pilot training, and sadly to investigate accidents or record system failures. Recordings will be from instrumentation and from audio and video sources. Maintenance and configuration data is also stored for future use. Recent successes have been for legacy avionics, simulation and training systems as well as automatic test equipment.

Q) What in your mind is the correct storage technology?

Solid state flash memory is the preferred choice, but often backwards compatibility with the legacy system is the key, as new interfaces may require mechanical or software changes and/or system/aircraft requalification. The benefits of solid state in harsh operating conditions are well-established.

Q) What are the main customer storage demands?

Meeting performance and environmental specification is key, and price needs to take into account alongside long-term servicing costs and contracts that require contracted levels of availability. Aerospace customers need to meet performance requirements in challenging environments and to manage the consequences of any failure in the drive selection criteria.

Q) How are you assisting the OEMs and Primes with solutions that can be found embedded within systems connected with C4ISR technologies, mission, flight, simulation, training, and condition-based monitoring activities around the world?

Both military and civil customers need supporting where fleets require ongoing maintenance and life extension, but a computer subsystem refresh cannot be afforded. Often the legacy data storage is the weak link. When this can be replaced by new technology the legacy system and its existing software can be given a mid-life extension. If a firm out-of-service date for the platform is known, longer-term decisions can be made, but often that is not the case.

Q) Is there the perception that storage is generally perceived as an afterthought, especially in embedded design?

In some applications, data recording and storage is seen as an extra to the design as a reporting feature, although it is of course, an integral part of any IT product. In the aerospace world this has never been true, but engineers can only select the best technology available at the design stage, which may lead manufacture and product end of life (EOL) by many years. Avionics, simulation and training and automatic test equipment (ATE) is a case in point. Even the best conventional disk and tape drives require reasonable environmental conditions to perform well and can never match the Mean Time Between Failure (MTBF) of solid state.

Q) Is it your experience that technology moves on so fast and aerospace so slow that in some cases the initial requirement has become obsolete?

Yes, this is certainly true of data storage, and often true of the initial aerospace requirement. However, not only is it possible to deliver fit, form and function replacements for legacy storage devices more than thirty years old, it is also possible to provide features never conceived of at the original design point, but regarded as essential today. For example, off- and on-line backup via Ethernet connection or rugged removable flash media, duplicate media for additional data security, and encryption or other protection against an illegally acquired asset.

Q) Why is obsolescence in memory and storage increasingly more important when designing and developing systems especially those that need to run for many years without fault?

SSDs SCSIFlash (CF) network drive

Memory technology has historically been driven firstly by desktop computing, then gaming and mobile communications, but is now driven by data servers and cloud computing. The interface standards used to interconnect storage products with the host are also subject to rapid change driven by the need for performance. Product form factors are also driven by the need for small size, weight and low power consumption. Aerospace customers and designers need to be aware of the latest technology and plan to future proof their designs, bearing in mind that often the latest parts take some time to pass reliability and qualification testing for use in harsh environments.

Q) Do you provide a complete service that covers potential obsolescence issues? For example, what happens if a manufacturer issues an end of life notification?

Yes, in general. We are governed by our suppliers product planning, but work closely with them to ensure our products remain supportable. This includes early EOL warnings. To some extent we are buffered from the memory device level interface specification by the legacy interface we are required to emulate.

Q) Would you say that COTS still isnt fit for purpose, i.e. specialist kit requires specialist storage?

It is recognised that commercial systems and storage products may not work well or at all for long periods in hot, humid, high vibration, and extreme temperature cycling applications. Equally important is that commercial systems often do not have change control and configuration discipline to ensure subsequent purchases are made to the same specification. For COTS or MOTS (modified COTS) solutions, industrial solid state flash memory is usually suitable for the majority of applications. It all depends on the specification.

Q) Are manufacturers of storage upping their game?

SSD has worked with leading customers in key market sectors to provide our networked Touchless Removable drive solutions. Customers benefit from access to systems via our Direct Ethernet port from a host system. This allows data to be kept in a digital library located anywhere within the organisation without the need for physical media.

Many of the flash lines SSD support are fully compliant with aerospace and defence standards

Direct Ethernet is also available on our hard disk emulations, which allows a full copy to be remotely taken of a system drive and restored as a bootable image. This dramatically reduces the time taken to rebuild systems in the event of data corruption. SMART is used as an excellent means of monitoring the remaining life of Flash media.

Q) What kind of industry landscape will we be faced with when everything gets back to a new normal?

Businesses have become more cost-conscious, with reserves and working capital hard hit despite support from the Government for some companies. It is anticipated that life extensions and out-of-service dates will be extended for reliable systems. Sustainability and energy consumption in developing new products is also driving new product investment decisions.

Q) Where to next for your company?

Were looking at the development of alternative interface replacement devices to supplement the existing SCSI and IDE ranges. Were also investigating offering system level support to engineers using our proprietary technology and experience.

https://solidstatedisks.co.uk

Subscribe to our FREE Newsletter

Follow this link:
The age of information Aerospace Manufacturing - Aerospace Manufacturing

JK Group Unveils Sustainability Initiatives – Covering the Printing Inks, Coatings and Allied Industries – Ink World – Ink World Magazine

JK Group, part of Dover Digital Printing and Dover, announced several new initiatives that support improved sustainability.

JK Group said it developed a new way of packaging its reactive inks to reduce its environmental footprint, while also releasing an extended shelf life across all of its ink ranges.

The company's Kiian brand recently launched a new reactive ink series called Digistar Bellagio, with one of the new departures for this range being its Bag-in-Box (BiB) packaging.

Through this environmentally-friendly initiative, all reactive inks will now be packed in flexible, multilayered plastic bags, which are incorporated into a cardboard outer shell.

The system has several advantages and represents an 80% reduction in the use of plastic compared to traditional high-density polyethylene containers of a similar capacity, according to JK Group.

Additionally, the reduced packaging creates a reduction in shipping and warehouse space, leading to lower transport and storage costs and less environmental impact across the supply chain, according to JK Group.

"We are thrilled about these initiatives because not only are they better for the planet, but also for our customers, who are looking for cost-efficient ways to reduce their environmental impact. This represents a continued effort by all of our companies to improve the sustainability of our products," said Abhi Agrawal, president of Dover Digital Printing.

JK Group also announced a shelf life extension of all of its ink series. Harnessing continuous improvements in performance brought about by research and development activities, the company has conducted an in-depth analysis of its ink formulations, including stress tests, to determine more precisely how long they will last on the shelf.

The resulting extension of shelf life means improvements for stock management and order rationalization, enabling efficiency and cost savings.

See the original post here:
JK Group Unveils Sustainability Initiatives - Covering the Printing Inks, Coatings and Allied Industries - Ink World - Ink World Magazine

Market Assessment of Pyrroloquinoline Quinone Industry: Growth Drivers by Top Players like Haotian Pharm, Doctor’s Best, Health Thru Nutrition, Life…

Pyrroloquinoline Quinone Market Latest Research Report 2021- 2026 covers a complete market scenario across the globe with a detailed industry analysis of major key players like Haotian Pharm, Doctors Best, Health Thru Nutrition, Life Extension, NOW Foods, Swanson, etc. This report provides strategic recommendations consulted by the industrial experts including market forecasts, profit, supply, raw materials, cost structures, investment landscape, latest market trends, demands, and much more.

The report begins from overview of the Industry Chain structure, and describes the industry environment, then analyses the market size and forecast of Pyrroloquinoline Quinone by product, region, and application, in addition, this report introduces the market competition situation among the vendors, market price analysis, and value chain features are covered in this report.

To Get Premium Quality Sample copy of Pyrroloquinoline Quinone Market Report with Complete TOC, Figures & Graphs. Connect with us athttps://www.affluencemarketreports.com/industry-analysis/request-sample/1286984/

The Major Players included in the Pyrroloquinoline Quinone Market are:

Pyrroloquinoline Quinone Market Segmentation:

Pyrroloquinoline Quinone market is split by Type and by Application. For the period 2018-2026, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market Segmentation by Type:

Market Segmentation by Applications:

Promising Regions & Countries Mentioned in Pyrroloquinoline Quinone Market Report:

For more Customization in Pyrroloquinoline Quinone Market Report, Connect with us at https://www.affluencemarketreports.com/industry-analysis/request-inquiry/1286984/

The Study Objectives of Pyrroloquinoline Quinone Market Report are:

Major Points Covered in Table of Content are:

Get a Discount on Pyrroloquinoline Quinone Market Report at https://www.affluencemarketreports.com/industry-analysis/request-discount/1286984/

About Affluence:

Affluence Market Reports is the next generation of all your research needs with a strong grapple on the worldwide market for industries, organizations, and governments. Our aim is to deliver exemplary reports that meet the definite needs of clients, which offers an adequate business technique, planning, and competitive landscape for new and existing industries that will develop your business needs.

We provide a premium in-depth statistical approach, a 360-degree market view that includes detailed segmentation, key trends, strategic recommendations, growth figures, Cost Analysis, new progress, evolving technologies, and forecasts by authentic agencies.

For More Details Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone Number:

U.S: +1-(424) 256-1722

U.K.: +44 1158 88 1333

Email: sales@affluencemarketreports.com

Website: http://www.affluencemarketreports.com

Read the original:
Market Assessment of Pyrroloquinoline Quinone Industry: Growth Drivers by Top Players like Haotian Pharm, Doctor's Best, Health Thru Nutrition, Life...

Northrop Grumman and Intelsat make history with Docking of 2nd Mission Extension Vehicle – Sea News

Northrop Grumman Corporation (NYSE: NOC) and the companys wholly-owned subsidiary, SpaceLogistics LLC, have successfully completed the docking of the Mission Extension Vehicle-2 (MEV-2) to the Intelsat 10-02 (IS-10-02) commercial communications satellite to deliver life-extension services.

Northrop Grumman is the only provider of flight-proven life extension services for satellites, and this is the second time the two companies have docked commercial spacecraft in orbit. Northrop Grummans MEV-1 made history when it successfully docked to the Intelsat 901 (IS-901) satellite in February 2020. Unlike MEV-1, which docked above the GEO orbit before moving IS-901 back into service, MEV-2 docked with IS-10-02 directly in its operational GEO orbital location.

Todays successful docking of our second Mission Extension Vehicle further demonstrates the reliability, safety and utility of in-space logistics, said Tom Wilson, vice president, strategic space systems, Northrop Grumman and president, SpaceLogistics LLC. The success of this mission paves the way for our second generation of servicing satellites and robotics, offering flexibility and resiliency for both commercial and government satellite operators, which can enable entirely new classes of missions.

MEV-2 will provide five years of service to IS-10-02 before undocking and moving on to provide services for a new mission. IS-10-02 delivers broadband and media distribution services to Intelsat customers across Europe, the Middle East, Africa and South America; it is a key satellite in the Intelsat-Telenor Satellite 1 West video neighborhood, which distributes more than 900 channels to some 18 million TV households across Europe. Telenor Satellite own about half of IS-10-02s Ku band payload, which it markets as THOR 10-02 and contributed to todays successful mission.

Intelsat has pioneered innovations in space-based technology for more than five decades. We are proud to work side by side with Northrop Grumman on todays groundbreaking mission, the first-ever docking of a communications satellite in GEO orbit, said Intelsat Chief Services Officer Mike DeMarco. Space servicing is a valuable tool for Intelsat in extending the high-quality service experience that our customers depend upon. Northrop Grummans MEV technology has helped us extend the life of two high-performing satellites, while focusing our innovation capital on advancing the Intelsat next-generation network this technology is a win-win for us.

The Mission Extension Vehicle is the first in Northrop Grummans lineup of satellite servicing vehicles, but following last years robotic servicing mission award from DARPA, the company is working with the agency on a mission that will feature the first-ever commercial robotic servicing spacecraft. This mission will expand the market for satellite servicing of both commercial and government client satellites with advanced robotics using the companys Mission Robotics Vehicle (MRV) to conduct in-orbit repair, augmentation, assembly, detailed inspection and relocation of client satellites through robotics.

To further complement its on-orbit servicing portfolio, Northrop Grumman is leveraging model based systems engineering to develop its Mission Extension Pods (MEPs) which will also provide critical life extension services to aging satellites. The MRV will be used to install these pods on existing in-orbit commercial and government client satellites to extend their mission lives. The company is targeting 2024 for launch of both the MRV and the initial MEPs.

Sea News, April 15

Read more:
Northrop Grumman and Intelsat make history with Docking of 2nd Mission Extension Vehicle - Sea News

PEF can become the ‘standard in the food and drink industry’, says plastics producer – FoodNavigator.com

Dutch biochemical company Avantium says it is on track to open its first commercial production plant by the end of 2023. The facility in Delfzijl, the Netherlands, will produce 5,000 metric tonnes of FDCA per annum. FDCA is the key building block for polyethylene furanoate (PEF), a 100% plant-based, fully recyclable biopolyester. According to Avantium, PEF has the potential to replace various packaging materials such as PET, glass or aluminium in typical applications like bottles for soft drinks, water, alcoholic beverages and fruit juices. It expects bottles made with PEF to appear in Europes supermarkets by the beginning of 2024.

The Euronext Amsterdam-listed companys plans have been boosted after it raised around 28 million by issuing 5.2 million new shares and announced a deal with Belgium-based plastic packaging supplier Resilux for the supply of a fixed volume of PEF resin from the Avantium plant.

It has also signed collaboration agreements to develop sustainable bottles with an undisclosed major global food and beverage brand owner, the Japanese specialty chemical company Toyobo, the US specialty polyester film producer Terphane, and the Dutch beverage bottling company Refresco.

These deals come on top of Avantiums existing Plastic Bottle Project: a collaboration with Coca-Cola, spirits firm The Absolut Company and Carlsberg to jointly develop several PEF applications. This venture has already led to Carlsberg unveiling a prototype for the Green Fibre Bottle, which it claims is the worlds first paper beer bottle made from sustainably-sourced wood fibres that is both 100% bio-based and fully recyclable. The Danish beer giant has added its partnership with the project will assist its targets to achieve zero carbon emissions at its breweries and reduce its value chain carbon footprint by 30% by 2030.

Thanks to these developments, Avantium is confident PEF will be broadly introduced to the market around the globe and with high-value applications varying from monolayer bottles, multilayer bottles, and film.

Tom van Aken, Chief Executive Officer of Avantium told FoodNavigator that PEF plastic boasts attractive sustainability credentials because it uses no fossil fuels (unlike polyethylene terephthalate, or PET), can be recycled and will also degrade in nature much faster than normal plastics. It can further enable shelf life extension and thus help reduce waste.

The material is made using sugars from corn, wheat or beet and retains carbon dioxide better than conventional PET. If you have carbonated drinks, you need to keep the CO2 in your bottles, he explained. Our material is 5-10 times better than PET in keeping C02 in the bottle - so in that sense it's almost like glass in terms of how good it is in keeping carbonation in your drinks. But it is equally good for keeping air and oxygen out of the bottle so is good for everything that is sensitive to oxygen such as beer, juice, smoothies or coffee. It also has higher heat stability and is a bit stronger than PET, so it has significant safety performance benefits over it.

Around 300 million tonnes of plastic is made from fossil fuels globally every year, most of which is not recycled and can take hundreds of years to decompose. According to van Aken, many plastic bottles arent recycled because they use multiple polymers such as polyethylene,polyurethane and nylon in conjunction with PET. We're trying to replace these with a monolayer PEF film which can be easily recycled, he said. That will mean a substantial improvement over existing packaging materials.

Meanwhile, Avantium says its plant-based material degrades 100 times faster than PET. This is a product designed for recycling, stressed the CEO.But if it does end up in nature it will degrade much faster than conventional plastics.

Eventually, Avantium plans to use plant sugars from sustainable sourced biowaste so that the rise of plant plastic does not affect the global food supply chain. And while its target to make 5,000 tonnes is a modest one, it expects its production to grow as demand for renewable plastics climbs.

Cost remains a challenge for the scaling up of PEF production, however. While PET currently costs around 1 per kilo, for example, PEF is between 8-10 per kilo. However, van Aken said that's not a like-for-like comparison.We're competing against materials where they might be using nylon in sparling water bottles to keep the carbonation in the bottles,he eleborated.But the downside is that if the bottle is a combination of PET and nylon, it cannot be recycled. If you take away the nylon and replace it with PEF, you have a bottle than you can subsequently recycle because PEF and PET can mix and recycle.

He also pointed out that todays end consumers are prepared to pay a premium for sustainable products. More research shows that there's a significant percentage of consumers that are perfectly prepared to pay a few cents extra for something which is more sustainable. I think the contracts that we've just signed show that economics is not a prohibited aspect.

And while the companys current plans will suit "more niche high-value applications", he expects prices to drop as the company builds larger-scale plants.

From 2026 onwards, we expect the next stage will be to build larger-scale plants in Asia and the US which means the product will be built on a much larger scale and much more materials will become available at significantly lower cost. Then the material will compete with all glass packaging, all alumina cans and with many of the multi-layer packaging products that you see out there."

It can be used across the soft drinks sector in juice and waters, but also in everything that is air sensitive so coffee and meat packaging.

View post:
PEF can become the 'standard in the food and drink industry', says plastics producer - FoodNavigator.com

Belfast Harbour invests 2.5m in refurbishment of Terminal 1 – Belfast Newsletter

The programme of work, which represents a 2.5million investment by Belfast Harbour, will effectively renew and modernize the terminal infrastructure, extending its life span for a further 25 years. Work will include refurbishment of the berth ramp, the access walkways and the fenders.

Local contractors McLaughlin & Harvey has been engaged to deliver the project which is due to commence in early summer.

To facilitate these works the Belfast-Heysham service will operate from the Ballast Quay Terminal during the summer period.

Belfast Harbour has continued its long-term investment programme in port infrastructure in recent years, including the 40million redevelopment of Victoria Terminal 3 container terminal, with more than 20million invested in new cranes, and the installation of a new 15million two tier linkspan ramp at Victoria Terminal 2 ferry terminal to accommodate Stenas new Embla and Edda vessels on the Belfast- Liverpool route.

Michael Robinson, Port Director, Belfast Harbour said: We are continuing to invest in our port infrastructure and equipment that will help us achieve our goal of becoming the best regional port in the world.

Roll-On-Roll-Off freight, including on the Belfast to Heysham route, performed strongly last year, reflecting the importance of our freight traffic routes to Scotland and England and the essential supply chains we serve to the Northern Ireland economy. We want our facilities to be best in class and having undertaken a full structural assessment of the VT1 facilities we believe that making this 2.5million investment now will provide both this standard and a long-term life extension for the terminal.

John Mariner, McLaughlin & Harvey Contracts Director added: We are delighted to deliver another project for Belfast Harbour; building on our successful long-term relationship which includes Victoria Terminals 3 and 4. This project will be delivered using a local supply chain, and will utilise our extensive marine civil engineering expertise to support the harbour in its programme of continual investment to improve facilities in the port.

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

In order for us to continue to provide high quality and trusted local news on this free-to-read site, I am asking you to also please purchase a copy of our newspaper whenever you are able to do so.

Our journalists are highly trained and our content is independently regulated by IPSO to some of the most rigorous standards in the world. But being your eyes and ears comes at a price. So we need your support more than ever to buy our newspapers during this crisis.

With the coronavirus lockdown having a major impact on many of our local valued advertisers - and consequently the advertising that we receive - we are more reliant than ever on you helping us to provide you with news and information by buying a copy of our newspaper when you can safely.

You can also enjoy unlimited access to the best news from across Northern Ireland and the UK by subscribing to newsletter.co.uk

With a digital subscription, you can read more than five articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit https://www.newsletter.co.uk/subscriptions now to sign up.

More:
Belfast Harbour invests 2.5m in refurbishment of Terminal 1 - Belfast Newsletter

Springfield National Weather Service radar scheduled outage coming, will last about a week – KOLR – OzarksFirst.com

SPRINGFIELD, Mo. Beginning Thursday, February 25, 2021, the radar operated by the NOAA National Weather Service will be down for approximately seven days.

The planned outage is to replace the generator, fuel tanks, and accompanying components.

This update is important to support the radars operation during periods of commercial power outages, specifically when hazardous weather is present.

This generator update is the third major project of the NEXRAD Service Life Extension Program, a series of upgrades and replacements that will keep our nations radars viable into the 2030s.

NOAA National Weather Service, the United States Air Force, and the Federal Aviation Administration are investing about $150 million in the seven-year program. The first project was the installation of the new signal processor and the second project was the transmitter refurbishment. The two remaining projects are the refurbishment of the pedestal and equipment shelters. The Service Life Extension Program will complete in 2023.

During the outage, check data from adjacent radars including: Pleasant Hill/Kansas City (KEAX), St Louis (KLSX), Paducah, KY (KPAH), Memphis, TN (KNQA), Little Rock, AR (KLZK), Fort Smith, AR (KSRX), Tulsa, OK (KINX), Wichita, KS (KICT) and Topeka, KS (KTWX).

Go here to read the rest:
Springfield National Weather Service radar scheduled outage coming, will last about a week - KOLR - OzarksFirst.com

Global Military Aircraft Modernization and Upgrade and Retrofit Markets to 2024: Incorporation of CNS Systems in aircraft and Emergence of SVAB -…

Dublin, Feb. 25, 2021 (GLOBE NEWSWIRE) -- The "Global Military Aircraft Modernization and Upgrade and Retrofit Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The military aircraft modernization and upgrade and retrofit market is poised to grow by $ 2.61 bn during 2020-2024 progressing at a CAGR of 3% during the forecast period.

The market is driven by the incorporation of CNS systems in aircraft and emergence of SVAB.

The reports on military aircraft modernization and upgrade and retrofit market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The military aircraft modernization and upgrade and retrofit market analysis includes type segment and geographical landscapes.

This study identifies service life extension of military aircraft fleets as one of the prime reasons driving the military aircraft modernization and upgrade and retrofit market growth during the next few years.

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading military aircraft modernization and upgrade and retrofit market vendors that include BAE Systems Plc, Elbit Systems Ltd., Honeywell International Inc., Israel Aerospace Industries Ltd., L3Harris Technologies Inc., Lockheed Martin Corp., Northrop Grumman Corp., Raytheon Technologies Corp., Thales Group, and The Boeing Co..

Also, the military aircraft modernization and upgrade and retrofit market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/lyfiou

Follow this link:
Global Military Aircraft Modernization and Upgrade and Retrofit Markets to 2024: Incorporation of CNS Systems in aircraft and Emergence of SVAB -...

Real-Time Communication with Dreaming Person Possible, Says Study | The Weather Channel – Articles from The Weather Channel | weather.com – The…

Representational image

Can anyone perceive questions and provide answers in the midst of a vivid dream? It is possible, say researchers of a recent study whose results might sound like a real-life extension of the Hollywood blockbuster Inception.

The findings of the study indicate that it is possible for people while dreaming to follow instructions, do simple math, answer yes-or-no questions, or tell the difference between different sensory stimuli.

"We found that individuals in REM sleep can interact with an experimenter and engage in real-time communication," said researcher Ken Paller from Northwestern University in the US. According to the researcher, dreamers are capable of comprehending questions, engaging in working-memory operations and producing answers.

"Most people might predict that this would not be possiblethat people would either wake up when asked a question or fail to answer and certainly not comprehend a question without misconstruing it," Paller said. But the research shows that people in dreams could respond using eye movements or by contracting facial muscles.

For the study, published in the journal Current Biology, the researchers evaluated 36 people who aimed to have a lucid dream, in which a person is aware they're dreaming. The researchers refer to it as "interactive dreaming."

The researchers said that future studies of dreaming could use these same methods to assess cognitive abilities during dreams versus wake. Outside of the laboratory, the methods could be used to help people in various ways, such as solving problems during sleep or offering nightmare sufferers novel ways to cope, the team noted.

**

The above article has been published from a wire source with minimal modifications to the headline and text.

See more here:
Real-Time Communication with Dreaming Person Possible, Says Study | The Weather Channel - Articles from The Weather Channel | weather.com - The...

Archives